

## AUTHOR INDEX FOR VOLUME 50

## A

- Abdel-Malek, S. *see* Robinson, W. E., Jr., 846  
 Adams, M. E. *see* Norris, T. M., 939  
 Ahluwalia, G. S., Gao, W.-Y., Mitsuya, H., and Johns, D. G. 2',3'-Didehydro-3'-deoxythymidine: Regulation of its Metabolic Activation by Modulators of Thymidine-5'-triphosphate Biosynthesis, 160  
 Ahmad, S. *see* Yazaki, T., 236  
 Aiyar, J. *see* Nguyen, A., 1672  
 Akerman, G. *see* Tew, K. D., 149  
 Akhtar, S. *see* Coulson, J. M., 314  
 Akil, H. *see* Cho, W., 1338  
 Alahari, S. K., Dean, N. M., Fisher, M. H., Delong, R., Manoharan, M., Tivel, K. L., and Juliano, R. L. Inhibition of Expression of the Multidrug Resistance-Associated P-Glycoprotein by Phosphorothioate and 5' Cholesterol-Conjugated Phosphorothioate Antisense Oligonucleotides, 808  
 Almaula, N., Ebersole, B. J., Ballesteros, J. A., Weinstein, H., and Sealfon, S. C. Contribution of a Helix 5 Locus to Selectivity of Hallucinogenic and Nonhallucinogenic Ligands for the Human 5-Hydroxytryptamine<sub>2A</sub> and 5-Hydroxytryptamine<sub>2C</sub> Receptors: Direct and Indirect Effects on Ligand Affinity Mediated by the Same Locus, 34  
 Alvaro, J. D., Tatro, J. B., Quillan, J. M., Fogliano, M., Eisenhard, M., Lerner, M. R., Nestler, E. J., and Duman, R. S. Morphine Down-regulates Melanocortin-4 Receptor Expression in Brain Regions that Mediate Opiate Addiction, 583  
 Alzola, E. S. *see* Azula, F. J., 367  
 Andrade, R. *see* Torres, G. E., 1316  
 André, C. *see* Lecoeur, S., 326  
 Andrews, A. M., Ladenheim, B., Epstein, C. J., Cadet, J. L., and Murphy, D. L. Transgenic Mice with High Levels of Superoxide Dismutase Activity are Protected from the Neurotoxic Effects of 2'-NH<sub>2</sub>-MPTP on Serotonergic and Noradrenergic Nerve Terminals, 1511  
 Angelotti, T. P. *see* Lin, Y.-F., 185  
 Animati, F., Arcamone, F., Bigioni, M., Capranico, G., Caserini, C., De Cesare, M., Lombardi, P., Pratesi, G., Salvatore, C., Supino, R., and Zunino, F. Biochemical and Pharmacological Activity of Novel 8-Fluoroanthracylines: Influence of Stereochemistry and Conformation, 603  
 Aoki, Y. *see* Minami, M., 1413  
 Aquaro, S. *see* Balzarini, J., 394  
 Aquaro, S. *see* Perno, C.-F., 359  
 Arai, H., and Escobedo, J. A. Angiotensin II Type 1 Receptor Signals through Raf-1 by a Protein Kinase C-Dependent, Ras-Independent Mechanism, 522  
 Arcamone, F. *see* Animati, F., 603  
 Arfken, C. L. *see* Torres, G. E., 1316  
 Arion, D., Fletcher, R. S., Borkow, G., Camarasa, M.-J., Balzarini, J., Dmitrienko, G. I., and Parniak, M. A. Differences in the Inhibition of Human Immunodeficiency Virus Type 1 Reverse Transcriptase DNA Polymerase Activity by Analogs of Nevirapine and [2',5'-bis-*o*-(*tert*-Butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'', 2''-oxathiole-2'',2''-dioxide)] (TSAO), 1057  
 Asai, T., Pelzer, S., and McDonald, T. F. Cyclic AMP-Independent Inhibition of Cardiac Calcium Current by Forskolin, 1262  
 Austin, C. A. *see* Cornarotti, M., 1463

- Azula, F. J., Alzola, E. S., Conde, M., Trueba, M., Macarulla, J. M., and Marino, A. Thrombin-Stimulated Phospholipase C Activity Is Inhibited without Visible Delay by a Rapid Increase in the Cyclic GMP Levels Induced by Sodium Nitroprusside, 367

## B

- Backlund, M. *see* Hedlund, E., 342  
 Backstrom, J. R. *see* Canton, H., 799  
 Baker, I. *see* Masserano, J. M., 1309  
 Baker, S. P. *see* Srinivas, M., 196  
 Baldwin, H. A. *see* Tindberg, N., 1065  
 Balestra, E. *see* Perno, C.-F., 359  
 Ballesteros, J. A. *see* Almaula, N., 34  
 Balzarini, J. *see* Arion, D., 1057  
 Balzarini, J. *see* Hatse, S., 1231  
 Balzarini, J. *see* Perno, C.-F., 359  
 Balzarini, J., Egberink, H., Hartmann, K., Cahard, D., Vahlenkamp, T., Thormar, H., De Clercq, E., and McGuigan, C. Antiretrovirus Specificity and Intracellular Metabolism of 2',3'-Didehydro-2',3'-dideoxythymidine (Stavudine) and Its 5'-Monophosphate Triester Prodrug So324, 1207  
 Balzarini, J., Pelemans, H., Aquaro, S., Perno, C.-F., Witvrouw, M., Schols, D., De Clercq, E., and Karlsson, A. Highly Favorable Antiviral Activity and Resistance Profile of the Novel Thiocarboxanilide Pentenyloxy Ether Derivatives UC-781 and UC-82 as Inhibitors of Human Immunodeficiency Virus Type 1 Replication, 394  
 Bamberger, U. *see* Liu, Z., 482  
 Bao, Y. *see* Itoh, S., 736  
 Barak, D. *see* Grosfeld, H., 639  
 Barber, R. *see* Morrison, K. J., 692  
 Barbhaiya, H., McClain, R., IJzerman, A., and Rivkees, S. A. Site-Directed Mutagenesis of the Human A<sub>1</sub> Adenosine Receptor: Influences of Acidic and Hydroxy Residues in the First Four Transmembrane Domains on Ligand Binding, 1635  
 Barker, E. L. *see* Canton, H., 799  
 Barker, E. L., and Blakely, R. D. Identification of a Single Amino Acid, Phenylalanine 586, That Is Responsible for High Affinity Interactions of Tricyclic Antidepressants with the Human Serotonin Transporter, 957  
 Barnard, E. A. *see* Webb, T. E., 258  
 Barone, L. *see* Tew, K. D., 149  
 Bartholdi, M. *see* Feldman, R. I., 1346  
 Barwick, J. L., Quattrochi, L. C., Mills, A. S., Potenza, C., Tukey, R. H., and Guzelian, P. S. Trans-species Gene Transfer for Analysis of Glucocorticoid-Inducible Transcriptional Activation of Transiently Expressed Human CYP3A4 and Rabbit CYP3A6 in Primary Cultures of Adult Rat and Rabbit Hepatocytes, 10  
 Bass, R. T., Buckwalter, B. L., Patel, B. P., Pausch, M. H., Price, L. A., Strnad, J., and Hadcock, J. R. Identification and Characterization of Novel Somatostatin Antagonists, 709  
 Bateson, A. N. *see* Webb, T. E., 258  
 Bayard, F. *see* Mesange, F., 75  
 Beall, H. D. *see* Gustafson, D. L., 728  
 Beaune, P. H. *see* Lecoeur, S., 326  
 Beavers, L. *see* Gehlert, D. R., 112  
 Beck-Sickinger, A. G. *see* Sautel, M., 285  
 Bédard, P. J. *see* Morissette, M., 1073  
 Behrends, S. *see* Schrammel, A., 1

- Beinborn, M. *see* Schmitz, F., 436  
 Beindl, W., Mitterauer, T., Hohenegger, M., Ijzerman, A. P., Nanoff, C., and Freissmuth, M. Inhibition of Receptor/G Protein Coupling by Suramin Analogues, 415  
 Belardinelli, L. *see* Srinivas, M., 196  
 Bell, G. I. *see* Glaum, S. R., 230  
 Benke, D. *see* Knoflach, F., 1253  
 Benson, J. A. *see* Knoflach, F., 1253  
 Berg, K. A., Maayani, S., and Clarke, W. P. 5-Hydroxytryptamine<sub>2C</sub> Receptor Activation Inhibits 5-Hydroxytryptamine<sub>1B</sub>-like Receptor Function via Arachidonic Acid Metabolism, 1017  
 Berger, A., Bittman, R., Schmidt, R. R., and Spiegel, S. Structural Requirements of Sphingosylphosphocholine and Sphingosine-1-phosphate for Stimulation of Activator Protein-1 Activity, 451  
 Berry, S. A., Shah, M. C., Khan, N., and Roth, B. L. Rapid Agonist-Induced Internalization of the 5-Hydroxytryptamine<sub>2A</sub> Receptor Occurs via the Endosome Pathway *In Vitro*, 306  
 Bertrand, D. *see* Yu, D., 1010  
 Betz, H. *see* Schmieden, V., 1200  
 Bhattacharya, S., and Linden, J. Effects of Long-Term Treatment with the Allosteric Enhancer, PD81,723, on Chinese Hamster Ovary Cells Expressing Recombinant Human A<sub>1</sub> Adenosine Receptors, 104  
 Biancalana, S. *see* Wu, J. M., 1355  
 Biggers, M. S. *see* Nguyen, A., 1672  
 Bigioni, M. *see* Animati, F., 603  
 Billings, R. E. *see* Duval, D. L., 277  
 Bilodeau, L. *see* Grazzini, E., 1273  
 Bindokas, V. P. *see* Glaum, S. R., 230  
 Birnbaumer, L. *see* Suh-Kim, H., 1330  
 Birnbaumer, M. *see* Innamorati, G., 467  
 Birnbaumer, M. *see* Oksche, A., 820  
 Bittman, R. *see* Berger, A., 451  
 Bittman, R. *see* Liliom, K., 616  
 Blagbrough, I. S. *see* Norris, T. M., 939  
 Blakely, R. D. *see* Barker, E. L., 957  
 Blakely, R. D. *see* Melikian, H. E., 266  
 Blanchet, P. J. *see* Morissette, M., 1073  
 Blaustein, M. P. *see* Rogowski, R. S., 1167  
 Bockaert, J. *see* Gomez, J., 923  
 Bocos, C. *see* Corton, J. C., 1157  
 Bogatkewitsch, G. S., Lenz, W., Jakobs, K. H., and Van Koppen, C. J. Receptor Internalization Delays m4 Muscarinic Acetylcholine Receptor Resensitization at the Plasma Membrane, 424  
 Boissard, C. G. *see* Gribkoff, V. K., 206  
 Bolton, E. M. *see* Gustafson, D. L., 728  
 Borkow, G. *see* Arion, D., 1057  
 Bouchelet, I., Cohen, Z., Case, B., Séguéla, P., and Hamel, E. Differential Expression of Sumatriptan-Sensitive 5-Hydroxytryptamine Receptors in Human Trigeminal Ganglia and Cerebral Blood Vessels, 219  
 Bourne, H. R. *see* Conklin, B. R., 885  
 Bouvier, M. *see* Chidiac, P., 662  
 Boyer, J. L., Romero-Avila, T., Schachter, J. B., and Harden, T. K. Identification of Competitive Antagonists of the P2Y<sub>1</sub> Receptor, 1323  
 Boyle, J. E. *see* Zeldin, D. C., 1111  
 Brabet, I. *see* Gomez, J., 923  
 Bracamontes, J. *see* Ueno, S., 931  
 Bradford, B. U. *see* Iimuro, Y., 656  
 Bray, P. G., Hawley, S. R., Mungthin, M., and Ward, S. A. Physicochemical Properties Correlated with Drug Resistance and the Reversal of Drug Resistance in *Plasmodium falciparum*, 1559  
 Bray, P. G., Hawley, S. R., and Ward, S. A. 4-Aminoquinoline Resistance of *Plasmodium falciparum*: Insights from the Study of Amodiaquine Uptake, 1551  
 Brenner, D. A. *see* Iimuro, Y., 656  
 Brown, A. M. *see* Kiehn, J., 380  
 Brown, R. *see* Vasey, P. A., 1536  
 Browning, M. D. *see* Lin, Y.-F., 185  
 Bruno, V. *see* Thomsen, C., 6  
 Bruns, M. J. *see* Nguyen, A., 1672  
 Brust, P. F. *see* McCool, B. A., 912  
 Buckwalter, B. L. *see* Bass, R. T., 709  
 Bullock, A. J. *see* Murphy, C. T., 1223  
 Burgard, E. C., Tietz, E. I., Neelands, T. R., and Macdonald, R. L. Properties of Recombinant  $\gamma$ -Aminobutyric Acid<sub>A</sub> Receptor Isoforms Containing the  $\alpha 5$  Subunit Subtype, 119  
 Burman, M. *see* Jacobitz, S., 891  
 Burnstock, G. *see* Webb, T. E., 258
- C**
- Cadet, J. L. *see* Andrews, A. M., 1511  
 Cahalan, M. D. *see* Nguyen, A., 1672  
 Cahard, D. *see* Balzarini, J., 1207  
 Cai, J. J. *see* Yu, H., 549  
 Calderon, S. N. *see* Varga, E. V., 1619  
 Calò, R. *see* Perno, C.-F., 359  
 Calon, F. *see* Morissette, M., 1073  
 Camarasa, M.-J. *see* Arion, D., 1057  
 Canniff, P. C. *see* Nguyen, A., 1672  
 Canonico, P. L. *see* Cavallaro, S., 60  
 Canton, H., Emeson, R. B., Barker, E. L., Backstrom, J. R., Lu, J. T., Chang, M. S., and Sanders-Bush, E. Identification, Molecular Cloning, and Distribution of a Short Variant of the 5-Hydroxytryptamine<sub>2C</sub> Receptor Produced by Alternative Splicing, 799  
 Capranico, G. *see* Animati, F., 603  
 Capranico, G. *see* Cornarotti, M., 1463  
 Capranico, G. *see* Sissi, C., 838  
 Cardenas, M. E. *see* Zhu, D., 506  
 Carsrud, N. D. V. *see* Morrison, K. J., 692  
 Carter, D. B. *see* Knoflach, F., 1253  
 Cascieri, M. A. *see* Fong, T. M., 1605  
 Case, B. *see* Bouchelet, I., 219  
 Caserini, C. *see* Animati, F., 603  
 Cass, C. E. *see* Yao, S. Y. M., 1529, 388  
 Catterall, W. A. *see* Johnson, B. D., 1387  
 Cattley, R. C. *see* Corton, J. C., 1157  
 Cavallaro, S., Copani, A., D'Agata, V., Musco, S., Petralia, S., Ventra, C., Stivala, F., Travali, S., and Canonico, P. L. Pituitary Adenylate Cyclase Activating Polypeptide Prevents Apoptosis in Cultured Cerebellar Granule Neurons, 60  
 Cenci, A. *see* Perno, C.-F., 359  
 Chahlavi, A. *see* Yazaki, T., 236  
 Chance, R. E. *see* Gehlert, D. R., 112  
 Chandy, K. G. *see* Nguyen, A., 1672  
 Chang, K.-J. *see* Li, L.-Y., 599  
 Chang, M. S. *see* Canton, H., 799  
 Changeux, J.-P. *see* Yu, D., 1010  
 Chantry, A. *see* Coulson, J. M., 314  
 Chao, J. *see* Williams, K., 701  
 Chavkin, C. *see* Simmons, M. L., 80  
 Chen, J.-C. *see* Yu, S.-M., 1000  
 Chen, L. *see* Xu, Y., 1495  
 Chen, M. S. *see* Cihlar, T., 1502  
 Chen, S.-F. *see* Yu, S.-M., 1000  
 Cheng, E. *see* Lee, N. H., 140  
 Chidiac, P., Nouet, S., and Bouvier, M. Agonist-Induced Modulation of Inverse Agonist Efficacy at the  $\beta_2$ -Adrenergic Receptor, 662  
 Chieng, B., Connor, M., and Christie, M. J. The  $\mu$ -Opioid Receptor Antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH<sub>2</sub> (CTOP) [but not D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH<sub>2</sub> (CTAP)] Produces a Nonopioid Receptor-Mediated Increase in K<sup>+</sup> Conductance of Rat Locus Coeruleus Neurons, 650

- Chignell, C. F. *see* Reszka, K. J., 1612  
Chiu, T. T., Yung, L. Y., and Wong, Y. H. Inverse Agonistic Effect of ICI-174,864 on the Cloned  $\delta$ -Opioid Receptor: Role of G Protein and Adenylyl Cyclase Activation, 1651  
Cho, W., Taylor, L. P., and Akil, H. Mutagenesis of Residues Adjacent to Transmembrane Prolines Alters  $D_1$  Dopamine Receptor Binding and Signal Transduction, 1338  
Chow, S. A. *see* Robinson, W. E., Jr., 846  
Christie, M. J. *see* Chieng, B., 650  
Cihlar, T., and Chen, M. S. Identification of Enzymes Catalyzing Two-Step Phosphorylation of Cidofovir and the Effect of Cytomegalovirus Infection on Their Activities in Host Cells, 1502  
Claire, D. C. *see* Lawrence, J. W., 1178  
Clark, R. B. *see* Morrison, K. J., 692  
Clarke, W. P. *see* Berg, K. A., 1017  
Cline, R. T. *see* Lee, N. H., 140  
Cloëz-Tayarani, I. *see* Massot, O., 752  
Cohen, G. M. *see* MacFarlane, M., 900  
Cohen, Z. *see* Bouchelet, I., 219  
Collier, J. *see* Duval, D. L., 277  
Collins, J. H. *see* Rogowski, R. S., 1167  
Conde, M. *see* Azula, F. J., 367  
Conklin, B. R., Herzmark, P., Ishida, S., Voyno-Yasenetskaya, T. A., Sun, Y., Farfel, Z., and Bourne, H. R. Carboxyl-Terminal Mutations of  $G_{\alpha_q}$  and  $G_{\alpha_{12}}$  That Alter the Fidelity of Receptor Activation, 885  
Connor, M. *see* Chieng, B., 650  
Constantinou, A. *see* Ganapathi, R., 243  
Copani, A. *see* Cavallaro, S., 60  
Cordeiro, M. *see* Robinson, W. E., Jr., 846  
Cornarotti, M., Tinelli, S., Willmore, E., Zunino, F., Fisher, L. M., Austin, C. A., and Capranico, G. Drug Sensitivity and Sequence Specificity of Human Recombinant DNA Topoisomerases IIa (p170) and II $\beta$  (p180), 1463  
Corton, J. C., Bocos, E. S., Moreno, E. S., Merritt, A., Marsman, D. S., Sausen, P. J., Cattley, R. C., and Gustafsson, J.-A. Rat 17 $\beta$ -Hydroxysteroid Dehydrogenase Type IV Is a Novel Peroxisome Proliferator-Inducible Gene, 1157  
Coulson, J. M., Poyner, D. R., Chantry, A., Irwin, W. J., and Akhtar, S. A Nonantisense Sequence-Selective Effect of a Phosphorothioate Oligodeoxynucleotide Directed against the Epidermal Growth Factor Receptor in A431 Cells, 314  
Covey, D. F. *see* Wittmer, L. L., 1581  
Criscimagna, N. L. *see* Mathis, S. A., 128  
Cross, A. J. *see* Tindberg, N., 1065  
Curtis, N. R. *see* Patel, S., 1658
- D**
- D'Agata, V. *see* Cavallaro, S., 60  
Dalman, H. M. *see* Wade, S. M., 351  
Day, R. O. *see* Handel, M. L., 501  
Dean, N. M. *see* Alahari, S. K., 808  
Dean, N. M. *see* Yazaki, T., 236  
De Cesare, M. *see* Animati, F., 603  
De Clercq, E. *see* Balzarini, J., 1207, 394  
De Clercq, E. *see* Hatse, S., 1231  
Delarue, F. *see* Mesange, F., 75  
DeLong, R. *see* Alahari, S. K., 808  
De Meis, L. *see* Engender, S., 1243  
De Neef, P. *see* Van Rampelbergh, J., 1596  
De Souza, E. B. *see* Grigoriadis, D. E., 679  
Dickey, B. F. *see* Morrison, K. J., 692  
Dickson, J. *see* Oksche, A., 820  
Diehl, N. L., Kermode, J. C., and Shreeve, S. M. Direct Evidence for Functional Coupling of the Vasoactive Intestinal Peptide Receptor to  $G_{i3}$  in Native Lung Membranes, 624  
Ding, X. *see* Liu, C., 781  
Di Paolo, T. *see* Morissette, M., 1073  
Di Pierro, D. *see* Perno, C.-F., 359  
Dive, C. *see* MacFarlane, M., 900  
Dive, C. *see* Vasey, P. A., 1536  
Dmitrienko, G. I. *see* Arion, D., 1057  
Donovan, C. B. *see* Nguyen, A., 1672  
Dougherty, D. A. *see* Kearney, P. C., 1401  
Dragatsis, I. *see* Merkouris, M., 985  
Drewe, J. A. *see* Whittemore, E. R., 1364  
Drewett, J. G. *see* Olson, L. J., 430  
Dubocovich, M. L. *see* Witt-Enderby, P. A., 166  
Dubyak, G. *see* Ganapathi, R., 243  
Dudek, E. M. *see* Lin, Y.-F., 185  
Duman, R. S. *see* Alvaro, J. D., 583  
Duman, R. S. *see* Iredale, P. A., 1103  
Durrux, T. *see* Grazzini, E., 1273  
Duval, D. L., Miller, D. R., Collier, J., and Billings, R. E. Characterization of Hepatic Nitric Oxide Synthase: Identification as the Cytokine-Inducible Form Primarily Regulated by Oxidants, 277  
Dworetzky, S. I. *see* Gribkoff, V. K., 206
- E**
- Eberlein, W. *see* Sautel, M., 285  
Ebersole, B. J. *see* Almaula, N., 34  
Egberink, H. *see* Balzarini, J., 1207  
Eiselé, J.-L. *see* Yu, D., 1010  
Eisenhard, M. *see* Alvaro, J. D., 583  
Eisfelder, B. *see* Lobaugh, L. A., 493  
Eliasson, E., and Kenna, J. G. Cytochrome P450 2E1 Is a Cell Surface Autoantigen in Halothane Hepatitis, 573  
Emeson, R. B. *see* Canton, H., 799  
Emms, F. *see* Patel, S., 1658  
Engel, W. *see* Sautel, M., 285  
Engelender, S., and De Meis, L. Pharmacological Differentiation between Intracellular Calcium Pump Isoforms, 1243  
Epstein, C. J. *see* Andrews, A. M., 1511  
Esbenshade, T. A. *see* Theroux, T. L., 1376  
Esbenshade, T. A. *see* Zhong, H., 175  
Escobedo, J. A. *see* Arai, H., 522  
Eusebi, F. *see* Ragozzino, D., 1024  
Evans, C. J. *see* Piros, E. T., 947  
Evers, A. S. *see* Wittmer, L. L., 1581
- F**
- Falardeau, P. *see* Morissette, M., 1073  
Farber, J. L. *see* Glascott, P. A., Jr., 994  
Farfel, Z. *see* Conklin, B. R., 885  
Faye, J.-C. *see* Mesange, F., 75  
Feldman, R. I. *see* Wu, J. M., 1355  
Feldman, R. I., Bartholdi, M., and Wu, J. M. Bombesin-Like Peptide Receptor Subtypes Promote Mitogenesis, Which Requires Persistent Receptor Signaling, 1346  
Fernandez-Salguero, P. *see* Ryu, D.-Y., 443  
Figler, R. A., Graber, S. G., Lindorfer, M. A., Yasuda, H., Linden, J., and Garrison, J. C. Reconstitution of Recombinant Bovine A<sub>1</sub> Adenosine Receptors in Sf9 Cell Membranes with Recombinant G Proteins of Defined Composition, 1587  
Fillion, B. *see* Massot, O., 752  
Fillion, M.-P. *see* Massot, O., 752  
Fisher, L. M. *see* Cornarotti, M., 1463  
Fisher, M. H. *see* Alahari, S. K., 808  
Fletcher, R. S. *see* Arion, D., 1057  
Fogliano, M. *see* Alvaro, J. D., 583  
Foley, J. *see* Zeldin, D. C., 1111  
Fong, T. M., Yu, H., Huang, R.-R. C., Cascieri, M. A., and Swain, C. J. Relative Contribution of Polar Interactions and Conforma-

tional Compatibility to Antagonist Neurokinin-1-Receptor Binding, 1605

- Fraser, C. M. *see* Lee, N. H., 140  
 Freedman, S. B. *see* Patel, S., 1658  
 Freissmuth, M. *see* Beindl, W., 415  
 Freissmuth, M. *see* Hohenegger, M., 1443  
 Fugelli, A. *see* Massot, O., 752  
 Fujimori, A., Gupta, M., Hoki, Y., and Pommier, Y. Acquired Camptothecin Resistance of Human Breast Cancer MCF-7/C4 Cells with Normal Topoisomerase I and Elevated DNA Repair, 1472  
 Fukuhara, M. *see* Tohkin, M., 556

## G

- Gadski, R. *see* Gehlert, D. R., 112  
 Gallo-Payet, N. *see* Grazzini, E., 1273  
 Ganapathi, R., Constantinou, A., Kamath, N., Dubyak, G., Grabowski, D., and Krivacic, K. Resistance to Etoposide in Human Leukemia HL-60 Cells: Reduction in Drug-Induced DNA Cleavage Associated with Hypophosphorylation of Topoisomerase II Phosphopeptides, 243  
 Gao, W. *see* Iimuro, Y., 656  
 Gao, W.-Y. *see* Ahluwalia, G. S., 160  
 García-Sáinz, J. A. *see* Vázquez-Prado, J., 17  
 Garrison, J. C. *see* Figler, R. A., 1587  
 Gati, W. P. *see* Yao, S. Y. M., 1529  
 Gehlert, D. R., Schober, D. A., Beavers, L., Gadski, R., Hoffman, J. A., Smiley, D. L., Chance, R. E., Lundell, I., and Larhammar, D. Characterization of the Peptide Binding Requirements for the Cloned Human Pancreatic Polypeptide-Preferring Receptor, 112  
 Geoghagen, N. S. M. *see* Lee, N. H., 140  
 George, S. R. *see* Pak, Y., 1214  
 Georges, E. *see* Liu, Z., 482  
 Georgoussi, Z. *see* Merkouris, M., 985  
 Gesek, F. A.  $\alpha_2$ -Adrenergic Receptors Activate Phospholipase C in Renal Epithelial Cells, 407  
 Gibson, K. *see* Lobaugh, L. A., 493  
 Gilbert, B. A. *see* Xu, Y., 1495  
 Gilfor, E. *see* Glascott, P. A., Jr., 994  
 Gimble, J. M., Robinson, C. E., Wu, X., Kelly, K. A., Rodriguez, B. R., Kliewer, S. A., Lehmann, J. M., and Morris, D. C. Peroxisome Proliferator-Activated Receptor- $\gamma$  Activation by Thiazolidinediones Induces Adipogenesis in Bone Marrow Stromal Cells, 1087  
 Glascott, P. A., Jr., Tsyganskaya, M., Gilfor, E., Zern, M. A., and Farber, J. L. The Antioxidant Function of the Physiological Content of Vitamin C, 994  
 Glaum, S. R., Hara, M., Bindokas, V. P., Lee, C. C., Polonsky, K. S., Bell, G. I., and Miller, R. J. Leptin, the *Obese* Gene Product, Rapidly Modulates Synaptic Transmission in the Hypothalamus, 230  
 Glazer, R. I. *see* Yazaki, T., 236  
 Glick, D. *see* Loewenstein-Lichtenstein, Y., 1423  
 Gluzman, N. *see* Loewenstein-Lichtenstein, Y., 1423  
 Gomeza, J., Mary, S., Brabet, I., Parmentier, M.-L., Restituito, S., Bockaert, J., and Pin, J.-P. Coupling of Metabotropic Glutamate Receptors 2 and 4 to  $G_{\alpha 15}$ ,  $G_{\alpha 16}$ , and Chimeric  $G_{\alpha q1}$  Proteins: Characterization of New Antagonists, 923  
 Gommeren, W. *see* Leysen, J. E., 1567  
 Gong, L. *see* Masserano, J. M., 1309  
 Gonzalez, F. J. *see* Liu, C., 781  
 Gonzalez, F. J. *see* Peters, J. M., 67  
 Gonzalez, F. J. *see* Ryu, D.-Y., 443  
 Gorski, J. C. *see* Haehner, B. D., 52  
 Goulet, M. *see* Morissette, M., 1073  
 Gourlet, P. *see* Van Rampelbergh, J., 1596  
 Graber, S. G. *see* Figler, R. A., 1587  
 Grabowski, D. *see* Ganapathi, R., 243

Grant, A. O., John, J. E., Nesterenko, V. V., Starmer, C. F., and Moorman, J. R. The Role of Inactivation in Open-Channel Block of the Sodium Channel: Studies with Inactivation-Deficient Mutant Channels, 1643

- Grayson, D. R. *see* Zhu, W. J., 23  
 Grazzini, E., Durroux, T., Payet, M.-D., Bilodeau, L., Gallo-Payet, N., and Guillon, G. Membrane-Delimited G Protein-Mediated Coupling between  $V_{1a}$  Vasopressin Receptor and Dihydropyridine Binding Sites in Rat Glomerulosa Cells, 1273  
 Gribkoff, V. K. *see* Zhong, J., 631  
 Gribkoff, V. K., Lum-Ragan, J. T., Boissard, C. G., Post-Munson, D. J., Meanwell, N. A., Starrett, J. E., Jr., Kozlowski, E. S., Romine, J. L., Trojnacki, J. T., McKay, M. C., Zhong, J., and Dworetzky, S. I. Effects of Channel Modulators on Cloned Large-Conductance Calcium-Activated Potassium Channels, 206  
 Grigoriadis, D. E., Liu, X.-J., Vaughn, J., Palmer, S. F., True, C. D., Vale, W. W., Ling, N., and De Souza, E. B.  $^{125}\text{I}$ -Tyr $^0$ -Sauvagine: A Novel High Affinity Radioligand for the Pharmacological and Biochemical Study of Human Corticotropin-Releasing Factor $_{2a}$  Receptors, 679  
 Grimaldi, B. *see* Massot, O., 752  
 Grissmer, S. *see* Nguyen, A., 1672  
 Grissmer, S. *see* Rauer, H., 1625  
 Grosfeld, H., Barak, D., Ordentlich, A., Velan, B., and Shafferman, A. Interactions of Oxime Reactivators with Diethylphosphoryl Adducts of Human Acetylcholinesterase and Its Mutant Derivatives, 639  
 Guastella, J. *see* Ilyin, V. I., 1541  
 Guerrero, S. W. *see* Zhong, H., 175  
 Guillon, G. *see* Grazzini, E., 1273  
 Gunthorpe, M. J. *see* Hargreaves, A. C., 1284  
 Gupta, M. *see* Fujimori, A., 1472  
 Gustafson, D. L., Beall, H. D., Bolton, E. M., Ross, D., and Waldren, C. A. Expression of Human NAD(P)H:Quinone Oxidoreductase (DT-Diaphorase) in Chinese Hamster Ovary Cells: Effect on the Toxicity of Antitumor Quinones, 728  
 Gustafson, T. A. *see* Rogowski, R. S., 1167  
 Gustafsson, J.-A. *see* Corton, J. C., 1157  
 Gustafsson, J.-A. *see* Hedlund, E., 342  
 Gustafsson, J.-A. *see* Rowlands, J. C., 538  
 Gutman, G. A. *see* Nguyen, A., 1672  
 Guzelian, P. S. *see* Barwick, J. L., 10

## H

- Hadcock, J. R. *see* Bass, R. T., 709  
 Hadcock, J. R. *see* Price, L. A., 829  
 Haegeman, G. *see* Leysen, J. E., 1567  
 Haehner, B. D., Gorski, J. C., Vandenbranden, M., Wrighton, S. A., Janardan, S. K., Watkins, P. B., and Hall, S. D. Bimodal Distribution of Renal Cytochrome P450 3A Activity in Humans, 52  
 Hales, T. G. *see* Piro, E. T., 947  
 Hall, S. D. *see* Haehner, B. D., 52  
 Hamel, E. *see* Bouchelet, I., 219  
 Hamilton, B. J. *see* Knoflach, F., 1253  
 Handel, M. L., Watts, C. K. W., Sivertsen, S., Day, R. O., and Sutherland, R. L. D-Penicillamine Causes Free Radical-Dependent Inactivation of Activator Protein-1 DNA Binding, 501  
 Hankinson, O. *see* Zhang, J., 1454  
 Hannunniemi, R. *see* Selander, K. S., 1127  
 Hanson, D. C. *see* Nguyen, A., 1672  
 Hara, M. *see* Glaum, S. R., 230  
 Harden, T. K. *see* Boyer, J. L., 1323  
 Harden, T. K. *see* Nicholas, R. A., 224  
 Hargreaves, A. C., Gunthorpe, M. J., Taylor, C. W., and Lummis, S. C. R. Direct Inhibition of 5-Hydroxytryptamine $_3$  Receptors by Antagonists of L-type  $\text{Ca}^{2+}$  Channels, 1284  
 Härkönen, P. *see* Selander, K. S., 1127

- Harpold, M. M. *see* McCool, B. A., 912  
Harris, R. A. *see* Mascia, M. P., 402  
Hartmann, K. *see* Balzarini, J., 1207  
Hatse, S., De Clercq, E., and Balzarini, J. Evidence for Distinction of the Differentiation-Inducing Activities and Cytostatic Properties of 9-(2-Phosphonyl-methoxyethyl)adenine and a Variety of Differentiation-Inducing Agents in Human Erythroleukemia K562 Cells, 1231  
Hawley, S. R. *see* Bray, P. G., 1551, 1559  
Heckel, A. *see* Liu, Z., 482  
Hedlund, E., Wyss, A., Kainu, T., Backlund, M., Köhler, C., Pelto-Huikko, M., Gustafsson, J.-A., and Warner, M. Cytochrome P4502D4 in the Brain: Specific Neuronal Regulation by Clozapine and Toluene, 342  
Heinemann, S. F. *see* Krupp, J. J., 1680  
Heitman, J. *see* Zhu, D., 506  
Hen, R. *see* Massot, O., 752  
Henderson, D. *see* Webb, T. E., 258  
Herrmann-Frank, A. *see* Hohenegger, M., 1443  
Herzmark, P. *see* Conklin, B. R., 885  
Herzog, H. *see* Sautel, M., 285  
Heylen, L. *see* Leysen, J. E., 1567  
Hjorth, S. A., Thirstrup, K., and Schwartz, T. W. Radioligand-Dependent Discrepancy in Agonist Affinities Enhanced by Mutations in the  $\kappa$ -Opioid Receptor, 977  
Hoare, S. R. J., and Strange, P. G. Regulation of D<sub>2</sub> Dopamine Receptors by Amiloride and Amiloride Analogs, 1295  
Hockerman, G. H. *see* Johnson, B. D., 1387  
Hodgson, E. *see* Ryu, D.-Y., 443  
Hoffman, J. A. *see* Gehlert, D. R., 112  
Hohenegger, M. *see* Beindl, W., 415  
Hohenegger, M., Matyash, M., Poussu, K., Herrmann-Frank, A., Sarközi, S., Lehmann-Horn, F., and Freissmuth, M. Activation of the Skeletal Muscle Ryanodine Receptor by Suramin and Suramin Analogs, 1443  
Hoki, Y. *see* Fujimori, A., 1472  
Horisberger, J.-D. *see* Wang, X., 687  
Howell, S. B. *see* Perego, P., 1080  
Hruby, V. J. *see* Varga, E. V., 1619  
Hu, Y. *see* Wittmer, L. L., 1581  
Huang, R.-R. C. *see* Fong, T. M., 1605  
Hwa, J. *see* Zhao, M.-M., 1118  
Hwang, S. M. *see* Wong, A., 529

## I

- Ichikawa, A. *see* Nishigaki, N., 1031  
Igarashi, K. *see* Williams, K., 701  
Iimuro, Y., Bradford, B. U., Gao, W., Kadiiska, M., Mason, R. P., Stefanovic, B., Brenner, D. A., and Thurman, R. G. Detection of  $\alpha$ -Hydroxyethyl Free Radical Adducts in the Pancreas after Chronic Exposure to Alcohol in the Rat, 656  
Ijzerman, A. *see* Barbhuiya, H., 1635  
Ijzerman, A. P. *see* Beindl, W., 415  
Ikeda, H. *see* Yoshimura, M., 43  
Ilyin, V. I., Whitemore, E. R., Guastella, J., Weber, E., and Woodward, R. M. Subtype-Selective Inhibition of *N*-Methyl-D-aspartate Receptors by Haloperidol, 1541  
Ingelman-Sundberg, M. *see* Tindberg, N., 1065  
Innamorati, G., Sadeghi, H., and Birnbaumer, M. A Fully Active Nonglycosylated V2 Vasopressin Receptor, 467  
Iredale, P. A., Terwilliger, R., Widnell, K. L., Nestler, E. J., and Duman, R. S. Differential Regulation of Corticotropin-Releasing Factor<sub>1</sub> Receptor Expression by Stress and Agonist Treatments in Brain and Cultured Cells, 1103  
Irwin, W. J. *see* Coulson, J. M., 314  
Ishida, S. *see* Conklin, B. R., 885

- Itoh, S., Lu, R., Bao, Y., Morrow, J. D., Roberts, L. J., and Schuster, V. L. Structural Determinants of Substrates for the Prostaglandin Transporter PGT, 736

## J

- Jacobitz, S., McLaughlin, M. M., Livi, G. P., Burman, M., and Torphy, T. J. Mapping the Functional Domains of Human Recombinant Phosphodiesterase 4A: Structural Requirements for Catalytic Activity and Rolipram Binding, 891  
Jacobson, K. A. *see* Jiang, Q., 512  
Jakobs, K. H. *see* Bogatkewitsch, G. S., 424  
Jakobs, K. H. *see* Schmidt, M., 1038  
Jakobs, K. H. *see* Zhang, C., 864  
Janardan, S. K. *see* Haehner, B. D., 52  
Jenkins, S. *see* Vasey, P. A., 1536  
Jeon, Y. J., Yang, K.-H., Pulaski, J. T., and Kaminski, N. E. Attenuation of Inducible Nitric Oxide Synthase Gene Expression by  $\Delta^9$ -Tetrahydrocannabinol Is Mediated through the Inhibition of Nuclear Factor- $\kappa$ B/Rel Activation, 334  
Jeong, J. K., Stevens, J. L., Lau, S. S., and Monks, T. J. Quinone Thioether-Mediated DNA Damage, Growth Arrest, and *gadd153* Expression in Renal Proximal Tubular Epithelial Cells, 592  
Jezequel, S. *see* Schmieden, V., 1200  
Jia, Q. *see* Robinson, W. E., Jr., 846  
Jiang, Q., Rhee, A. M. V., Kim, J., Yehle, S., Wess, J., and Jacobson, K. A. Hydrophilic Side Chains in the Third and Seventh Transmembrane Helical Domains of Human A<sub>2A</sub> Adenosine Receptors Are Required for Ligand Recognition, 512  
Jimenez, G. *see* Perego, P., 1080  
Johanson, K. *see* Wong, A., 529  
John, J. E. *see* Grant, A. O., 1643  
Johns, D. G. *see* Ahluwalia, G. S., 160  
Johnson, B. D., Hockerman, G. H., Scheuer, T., and Catterall, W. A. Distinct Effects of Mutations in Transmembrane Segment IVS6 on Block of L-Type Calcium Channels by Structurally Similar Phenylalkylamines, 1387  
Johnson, G. L. *see* Lobaugh, L. A., 493  
Jones, N. A. *see* MacFarlane, M., 900  
Jones, N. A. *see* Vasey, P. A., 1536  
Jover, R., Lindberg, R. L. P., and Meyer, U. A. Role of Heme in Cytochrome P450 Transcription and Function in Mice Treated with Lead Acetate, 474  
Juliano, R. L. *see* Alahari, S. K., 808

## K

- Kadiiska, M. *see* Iimuro, Y., 656  
Kainu, T. *see* Hedlund, E., 342  
Kalkbrenner, M. *see* Wittmer, L. L., 1581  
Kamath, N. *see* Ganapathi, R., 243  
Kaminski, N. E. *see* Jeon, Y. J., 334  
Kan, H., Ruan, Y., and Malik, K. U. Involvement of Mitogen-Activated Protein Kinase and Translocation of Cytosolic Phospholipase A<sub>2</sub> to the Nuclear Envelope in Acetylcholine-Induced Prostacyclin Synthesis in Rabbit Coronary Endothelial Cells, 1139  
Kanzaki, M. *see* Nie, L., 763  
Kapur, J., and Macdonald, R. L. Pharmacological Properties of  $\gamma$ -Aminobutyric Acid<sub>A</sub> Receptors from Acutely Dissociated Rat Dentate Granule Cells, 458  
Karhukorpi, E.-K. *see* Selander, K. S., 1127  
Karlsson, A. *see* Balzarini, J., 394  
Kashiwagi, K. *see* Williams, K., 701  
Katao, Y. *see* Minami, M., 1413  
Kath, J. C. *see* Nguyen, A., 1672  
Katsumata, S. *see* Minami, M., 1413  
Kawai, K. *see* Varga, E. V., 1619

- Kearney, P. C., Nowak, M. W., Zhong, W., Silverman, S. K., Lester, H. A., and Dougherty, D. A. Dose-Response Relations for Unnatural Amino Acids at the Agonist Binding Site of the Nicotinic Acetylcholine Receptor: Tests with Novel Side Chains and with Several Agonists, 1401
- Kelly, K. A. *see* Gimble, J. M., 1087
- Kemp, M. C. *see* Ramamoorthy, L., 878
- Kenna, J. G. *see* Eliasson, E., 573
- Kennedy, A. P., Mangum, K. C., Linden, J., and Wells, J. N. Covalent Modification of Transmembrane Span III of the A<sub>1</sub> Adenosine Receptor with an Antagonist Photoaffinity Probe, 789
- Kermode, J. C. *see* Diehl, N. L., 624
- Khan, N. *see* Berry, S. A., 306
- Kieffer, B. *see* Matthes, H., 447
- Kiehn, J., Wible, B., Lacerda, A. E., and Brown, A. M. Mapping the Block of a Cloned Human Inward Rectifier Potassium Channel by Dofetilide, 380
- Kim, J. *see* Jiang, Q., 512
- King, B. F. *see* Webb, T. E., 258
- Klaassen, C. D. *see* Liu, L., 565
- Kliwer, S. A. *see* Gimble, J. M., 1087
- Knapp, R. J. *see* Varga, E. V., 1619
- Knoflach, F., Benke, D., Wang, Y., Scheurer, L., Lüddens, H., Hamilton, B. J., Carter, D. B., Mohler, H., and Benson, J. A. Pharmacological Modulation of the Diazepam-Insensitive Recombinant  $\gamma$ -Aminobutyric Acid<sub>A</sub> Receptors  $\alpha 4\beta 2\gamma 2$  and  $\alpha 6\beta 2\gamma 2$ , 1253
- Knoll, B. J. *see* Morrison, K. J., 692
- Koesling, D. *see* Schrammel, A., 1
- Köhler, C. *see* Hedlund, E., 342
- Kojima, I. *see* Nie, L., 763
- Kolakowski, L. F., Jr. *see* Schmitz, F., 436
- Komatsu, M., Schermerhorn, T., Straub, S. G., and Sharp, G. W. G. Pituitary Adenylate Cyclase-Activating Peptide, Carbachol, and Glucose Stimulate Insulin Release in the Absence of an Increase in Intracellular Ca<sup>2+</sup>, 1047
- Konidakis, G. *see* Merkouris, M., 985
- Kopin, A. S. *see* Schmitz, F., 436
- Kouvelas, A. *see* Pak, Y., 1214
- Kozlowski, E. S. *see* Gribkoff, V. K., 206
- Krause, J. E. *see* McCarron, K. E., 1189
- Krivacic, K. *see* Ganapathi, R., 243
- Krupp, J. J., Viessel, B., Heinemann, S. F., and Westbrook, G. L. Calcium-Dependent Inactivation of Recombinant *N*-Methyl-D-aspartate receptors Is NR2 Subunit Specific, 1680
- Kulaga, H. *see* Masserano, J. M., 1309
- Kulagowski, J. J. *see* Patel, S., 1658
- Kurose, K. *see* Tohkin, M., 556
- Lacerda, A. E. *see* Kiehn, J., 380
- Ladenheim, B. *see* Andrews, A. M., 1511
- Lakhlani, P. P., Lovinger, D. M., and Limbird, L. E. Genetic Evidence for Involvement of Multiple Effector Systems in  $\alpha 2A$ -Adrenergic Receptor Inhibition of Stimulus-Secretion Coupling, 96
- Landaman, R. S. *see* Varga, E. V., 1619
- Lanier, S. M. *see* Saulnier-Blache, J. S., 1432
- Larhammar, D. *see* Gehlert, D. R., 112
- Lau, S. S. *see* Jeong, J. K., 592
- Lau, Y.-T. *see* Yu, S.-M., 1000
- Law, P. Y. *see* Piro, E. T., 947
- Lawrence, J. W., Claire, D. C., Weissig, V., and Rowe, T. C. Delayed Cytotoxicity and Cleavage of Mitochondrial DNA in Ciprofloxacin-Treated Mammalian Cells, 1178
- Lazarowski, E. R. *see* Nicholas, R. A., 224
- Lazzarino, G. *see* Perno, C.-F., 359
- Lechner, M. C. *see* Wright, M. C., 856
- Lecoeur, S., André, C., and Beaune, P. H. Tienilic Acid-Induced Autoimmune Hepatitis: Anti-Liver and -Kidney Microsomal Type 2 Autoantibodies Recognize a Three-Site Conformational Epitope on Cytochrome P4502C9, 326
- Lee, C. C. *see* Glaum, S. R., 230
- Lee, H.-C. *see* Yu, H., 549
- Lee, N. H., Geoghagen, N. S. M., Cheng, E., Cline, R. T., and Fraser, C. M. Alanine Scanning Mutagenesis of Conserved Arginine/Lysine-Arginine/Lysine-X-X-Arginine/Lysine G Protein-Activating Motifs on m1 Muscarinic Acetylcholine Receptors, 140
- Lee, S. S. T. *see* Peters, J. M., 67
- Leeb-Lundberg, L. M. F. *see* Mathis, S. A., 128
- Leeson, P. D. *see* Patel, S., 1658
- Lehmann, J. M. *see* Gimble, J. M., 1087
- Lehmann-Horn, F. *see* Hohenegger, M., 1443
- Lenz, W. *see* Bogatkewitsch, G. S., 424
- Lepple-Wienhues, A. *see* Nguyen, A., 1672
- Lerner, M. R. *see* Alvaro, J. D., 583
- Lesage, A. S. *see* Leysen, J. E., 1567
- Lester, H. A. *see* Kearney, P. C., 1401
- Levi, P. E. *see* Ryu, D.-Y., 443
- Leysen, J. E., Gommeren, W., Heylen, L., Luyten, W. H. M. L., Van De Weyer, I., Vanhoenacker, P., Haegeman, G., Schotte, A., Van Gompel, P., Wouters, R., and Lesage, A. S. Alniditan, a New 5-Hydroxytryptamine<sub>1D</sub> Agonist and Migraine-Abortive Agent: Ligand-Binding Properties of Human 5-Hydroxytryptamine<sub>1D $\alpha$</sub> , Human 5-Hydroxytryptamine<sub>1D $\beta$</sub> , and Calf 5-Hydroxytryptamine<sub>1D</sub> Receptors Investigated with [<sup>3</sup>H]5-Hydroxytryptamine and [<sup>3</sup>H]Alniditan, 1567
- Lheureux, F. *see* Liu, Z., 482
- Li, L.-Y., and Chang, K.-J. The Stimulatory Effect of Opioids on Mitogen-Activated Protein Kinase in Chinese Hamster Ovary Cells Transfected to Express  $\mu$ -Opioid Receptors, 599
- Li, Q. *see* Nicholas, R. A., 224
- Li, X. *see* Varga, E. V., 1619
- Liebenhoff, U. *see* Oksche, A., 820
- Lilom, K., Bittman, R., Swords, B., and Tigyi, G. *N*-Palmitoyl-serine and *N*-Palmitoyl-tyrosine Phosphoric Acids Are Selective Competitive Antagonists of the Lysophosphatidic Acid Receptors, 616
- Limbird, L. E. *see* Lakhlani, P. P., 96
- Lin, Y.-F., Angelotti, T. P., Dudek, E. M., Browning, M. D., and Macdonald, R. L. Enhancement of Recombinant  $\alpha 1\beta 1\gamma 2L$   $\gamma$ -Aminobutyric Acid<sub>A</sub> Receptor Whole-Cell Currents by Protein Kinase C Is Mediated through Phosphorylation of Both  $\beta 1$  and  $\gamma 2L$  Subunits, 185
- Lindberg, R. L. P. *see* Jover, R., 474
- Linden, J. *see* Bhattacharya, S., 104
- Linden, J. *see* Figler, R. A., 1587
- Linden, J. *see* Kennedy, A. P., 789
- Lindley, C. J. *see* Murphy, C. T., 1223
- Lindorfer, M. A. *see* Figler, R. A., 1587
- Ling, N. *see* Grigoriadis, D. E., 679
- Liu, C., Zhuo, X., Gonzalez, F. J., and Ding, X. Baculovirus-Mediated Expression and Characterization of Rat CYP2A3 and Human CYP2A6: Role in Metabolic Activation of Nasal Toxicants, 781
- Liu, L., and Klaassen, C. D. Ontogenic and Hormonal Bases of Male-Dominant Rat Hepatic Sulfotransferases, 565
- Liu, X.-J. *see* Grigoriadis, D. E., 679
- Liu, Z., Lheureux, F., Pouliot, J.-F., Heckel, A., Bamberger, U., and Georges, E. BIBW22 BS, Potent Multidrug Resistance-Reversing Agent, Binds Directly to P-Glycoprotein and Accumulates in Drug-Resistant Cells, 482
- Livi, G. P. *see* Jacobitz, S., 891
- Lobaugh, L. A., Eisfelder, B., Gibson, K., Johnson, G. L., and Putney, J. W., Jr. Constitutive Activation of a Phosphoinositidase C-Linked G protein in Murine Fibroblasts Decreases Agonist-Stimulated Ca<sup>2+</sup> Mobilization, 493

## L

- Loewenstein-Lichtenstein, Y., Glick, D., Gluzman, N., Sternfeld, M., Zakut, H., and Soreq, H. Overlapping Drug Interaction Sites of Human Butyrylcholinesterase Dissected by Site-Directed Mutagenesis, 1423
- Lombardi, P. *see* Animati, F., 603
- Lovinger, D. M. *see* Lakhani, P. P., 96
- Lovinger, D. M. *see* McCool, B. A., 912
- Lowe, D. G. *see* Olson, L. J., 430
- Lu, J. T. *see* Canton, H., 799
- Lu, R. *see* Itoh, S., 736
- Lüddens, H. *see* Knoflach, F., 1253
- Lummis, S. C. R. *see* Hargreaves, A. C., 1284
- Lum-Ragan, J. T. *see* Gribkoff, V. K., 206
- Lundell, I. *see* Gehlert, D. R., 112
- Luyten, W. H. M. L. *see* Leysen, J. E., 1567
- M**
- Ma, J. *see* Zeldin, D. C., 1111
- Maayani, S. *see* Berg, K. A., 1017
- Macarulla, J. M. *see* Azula, F. J., 367
- Macdonald, R. L. *see* Burgard, E. C., 119
- Macdonald, R. L. *see* Kapur, J., 458
- Macdonald, R. L. *see* Lin, Y.-F., 185
- MacEwan, D. J., and Milligan, G. Inverse Agonist-Induced Up-Regulation of the Human  $\beta_2$ -Adrenoceptor in Transfected Neuroblastoma X Glioma Hybrid Cells, 1479
- MacFarlane, M., Jones, N. A., Dive, C., and Cohen, G. M. DNA-Damaging Agents Induce Both p53-Dependent and p53-Independent Apoptosis in Immature Thymocytes, 900
- Magyar, J., and Szabo, G. Effects of Volatile Anesthetics on the G Protein-Regulated Muscarinic Potassium Channel, 1520
- Makhoul, G. M. *see* Murthy, K. S., 870
- Malatynska, E. *see* Varga, E. V., 1619
- Malik, K. U. *see* Kan, H., 1139
- Mangum, K. C. *see* Kennedy, A. P., 789
- Manoharan, M. *see* Alahari, S. K., 808
- Marino, A. *see* Azula, F. J., 367
- Marinozzi, M. *see* Thomsen, C., 6
- Marsman, D. S. *see* Corton, J. C., 1157
- Marston, D. *see* Patel, S., 1658
- Martinez, R. *see* Sautel, M., 285
- Martuza, R. L. *see* Yazaki, T., 236
- Marwood, R. *see* Patel, S., 1658
- Mary, S. *see* Gomez, J., 923
- Mascia, M. P., Mihic, S. J., Valenzuela, C. F., Schofield, P. R., and Harris, R. A. A Single Amino Acid Determines Differences in Ethanol Actions on Strychnine-Sensitive Glycine Receptors, 402
- Mason, R. P. *see* Iimuro, Y., 656
- Masserano, J. M., Gong, L., Kulaga, H., Baker, I., and Wyatt, R. J. Dopamine Induces Apoptotic Cell Death of a Catecholaminergic Cell Line Derived from the Central Nervous System, 1309
- Massot, O., Rousselle, J.-C., Fillion, M.-P., Grimaldi, B., Cloëz-Tayarani, I., Fugelli, A., Prudhomme, N., Seguin, L., Rousseau, B., Plantefol, M., Hen, R., and Fillion, B. 5-Hydroxytryptamine-moduline, a New Endogenous Cerebral Peptide, Controls the Serotonergic Activity via Its Specific Interaction with 5-Hydroxytryptamine<sub>1B/1D</sub> Receptors, 752
- Masuko, T. *see* Williams, K., 701
- Mather, R. J. *see* Nguyen, A., 1672
- Mathis, S. A., Criscimagna, N. L., and Leeb-Lundberg, L. M. F. B1 and B2 Kinin Receptors Mediate Distinct Patterns of Intracellular  $Ca^{2+}$  Signaling in Single Cultured Vascular Smooth Muscle Cells, 128
- Matthes, H., Seward, E. P., Kieffer, B., and North, R. A. Functional Selectivity of Orphanin FQ for Its Receptor Coexpressed with Potassium Channel Subunits in *Xenopus laevis* Oocytes, 447
- Matyash, M. *see* Hohenegger, M., 1443
- Mayer, B. *see* Schrammel, A., 1
- McCarson, K. E., and Krause, J. E. The Neurokinin-1 Receptor Antagonist LY306,740 Blocks Nociception-Induced Increases in Dorsal Horn Neurokinin-1 Receptor Gene Expression, 1189
- McClain, R. *see* Barbhaiya, H., 1635
- McCool, B. A., Pin, J.-P., Brust, P. F., Harpold, M. M., and Lovinger, D. M. Functional Coupling of Rat Group II Metabotropic Glutamate Receptors to an  $\omega$ -Conotoxin GVIA-Sensitive Calcium Channel in Human Embryonic Kidney 293 Cells, 912
- McDonald, T. F. *see* Asai, T., 1262
- McEwan, I. J. *see* Rowlands, J. C., 538
- McGuigan, C. *see* Balzarini, J., 1207
- McKay, M. C. *see* Gribkoff, V. K., 206
- McLaughlin, M. M. *see* Jacobitz, S., 891
- McDevitt, P. *see* Wong, A., 529
- McNulty, D. *see* Wong, A., 529
- Meanwell, N. A. *see* Gribkoff, V. K., 206
- Megaritis, G. *see* Merkouris, M., 985
- Melikian, H. E., Ramamoorthy, S., Tate, C. G., and Blakely, R. D. Inability to N-Glycosylate the Human Norepinephrine Transporter Reduces Protein Stability, Surface Trafficking, and Transport Activity but Not Ligand Recognition, 266
- Merkouris, M., Dragatsis, I., Megaritis, G., Konidakis, G., Zioudrou, C., Milligan, G., and Georgoussi, Z. Identification of the Critical Domains of the  $\delta$ -Opioid Receptor Involved in G Protein Coupling Using Site-Specific Synthetic Peptides, 985
- Merritt, A. *see* Corton, J. C., 1157
- Mesange, F., Delarue, F., Puel, J., Bayard, F., and Faye, J.-C. Ligands of the Antiestrogen-Binding Site Are Able to Inhibit Virion Production of Human Immunodeficiency Virus 1-Infected Lymphocytes, 75
- Meunier, L. *see* Stewart, A. J., 1487
- Meyer, U. A. *see* Jover, R., 474
- Midoux, P. *see* Stewart, A. J., 1487
- Mihic, S. J. *see* Mascia, M. P., 402
- Miledi, R. *see* Ragozzino, D., 1024
- Miller, D. R. *see* Duval, D. L., 277
- Miller, R. J. *see* Glaum, S. R., 230
- Milligan, G. *see* MacEwan, D. J., 1479
- Milligan, G. *see* Merkouris, M., 985
- Millman, E. E. *see* Morrison, K. J., 692
- Mills, A. S. *see* Barwick, J. L., 10
- Mills, S. J. *see* Murphy, C. T., 1223
- Minami, M., Nakagawa, T., Seki, T., Onogi, T., Aoki, Y., Katao, Y., Katsumata, S., and Satoh, M. A Single Residue, Lys108, of the  $\delta$ -Opioid Receptor Prevents the  $\mu$ -Opioid-Selective Ligand [D-Ala<sup>2</sup>, N-MePhe<sup>4</sup>, Gly-ol<sup>5</sup>]Enkephalin from Binding to the  $\delta$ -Opioid Receptor, 1413
- Minehart, E. *see* Zhang, J., 1454
- Minneman, K. P. *see* Theroux, T. L., 1376
- Minneman, K. P. *see* Zhong, H., 175
- Mitchell, W. M. *see* Robinson, W. E., Jr., 846
- Mitsuya, H. *see* Ahluwalia, G. S., 160
- Mitterauer, T. *see* Beindl, W., 415
- Mizusura, A. *see* Varga, E. V., 1619
- Mogami, H. *see* Nie, L., 763
- Mohler, H. *see* Knoflach, F., 1253
- Molinoff, P. B. *see* Zhong, J., 631
- Mönkkönen, J. *see* Selander, K. S., 1127
- Monks, A. *see* Tew, K. D., 149
- Monks, T. J. *see* Jeong, J. K., 592
- Monsigny, M. *see* Stewart, A. J., 1487
- Montali, J. A. *see* Tew, K. D., 149
- Moomaw, C. R. *see* Zeldin, D. C., 1111
- Moore, R. H. *see* Morrison, K. J., 692
- Moorman, J. R. *see* Grant, A. O., 1643

- Moran, J. L., Siegel, D., Sun, X.-M., and Ross, D. Induction of Apoptosis by Benzene Metabolites in HL60 and CD34<sup>+</sup> Human Bone Marrow Progenitor Cells, 610
- Moreno, E. S. *see* Corton, J. C., 1157
- Morissette, M., Goulet, M., Calon, F., Falardeau, P., Blanchet, P. J., Bédard, P. J., and Di Paolo, T. Changes of D<sub>1</sub> and D<sub>2</sub> Dopamine Receptor mRNA in the Brains of Monkeys Lesioned with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Correction with Chronic Administration of L-3,4-Dihydroxyphenylalanine, 1073
- Morris, D. C. *see* Gimble, J. M., 1087
- Morrison, K. J., Moore, R. H., Carsrud, N. D. V., Trial, J., Millman, E. E., Tuvim, M., Clark, R. B., Barber, R., Dickey, B. F., and Knoll, B. J. Repetitive Endocytosis and Recycling of the  $\beta_2$ -Adrenergic Receptor during Agonist-Induced Steady State Redistribution, 692
- Morrow, J. D. *see* Itoh, S., 736
- Moya, E. *see* Norris, T. M., 939
- Müller, H. *see* Oksche, A., 820
- Mungthin, M. *see* Bray, P. G., 1559
- Munoz, M. *see* Sautel, M., 285
- Munson, P. J. *see* Rovati, G. E., 86
- Murata, Y. *see* Ragozzino, D., 1024
- Murphy, C. T., Bullock, A. J., Lindley, C. J., Mills, S. J., Riley, A. M., Potter, B. V. L., and Westwick, J. Enantiomers of *myo*-Inositol-1,3,4-trisphosphate and *myo*-Inositol-1,4,6-trisphosphate: Stereospecific Recognition by Cerebellar and Platelet *myo*-Inositol-1,4,5-trisphosphate Receptors, 1223
- Murphy, D. L. *see* Andrews, A. M., 1511
- Murphy, T. J. *see* Nickenig, G., 743
- Murthy, K. S., and Makhoul, G. M. Opioid  $\mu$ ,  $\delta$ , and  $\kappa$  Receptor-Induced Activation of Phospholipase C- $\beta$ 3 and Inhibition of Adenylyl Cyclase Is Mediated by G<sub>12</sub> and G<sub>6</sub> in Smooth Muscle, 870
- Musco, S. *see* Cavallaro, S., 60
- N**
- Nagase, H. *see* Varga, E. V., 1619
- Nakagawa, T. *see* Minami, M., 1413
- Nanoff, C. *see* Beindl, W., 415
- Neelands, T. R. *see* Burgard, E. C., 119
- Negishi, M. *see* Nishigaki, N., 1031
- Nehls, C. *see* Schmidt, M., 1038
- Nesterenko, V. V. *see* Grant, A. O., 1643
- Nestler, E. J. *see* Alvaro, J. D., 583
- Nestler, E. J. *see* Iredale, P. A., 1103
- Neubig, R. R. *see* Wade, S. M., 351
- Neve, K. A. *see* Watts, V. J., 966
- Ng, A. M. L. *see* Yao, S. Y. M., 1529
- Nguyen, A., Kath, J. C., Hanson, D. C., Biggers, M. S., Canniff, P. C., Donovan, C. B., Mather, R. J., Bruns, M. J., Rauer, H., Aiyar, J., Lepple-Wienhues, A., Gutman, G. A., Grissmer, S., Cahalan, M. D., and Chandy, K. G. Novel Nonpeptide Agents Potently Block the C-Type Inactivated Conformation of Kv1.3 and Suppress T Cell Activation, 1672
- Nicholas, R. A., Watt, W. C., Lazarowski, E. R., Li, Q., and Harden, T. K. Uridine Nucleotide Selectivity of Three Phospholipase C-Activating P<sub>2</sub> Receptors: Identification of a UDP-Selective, a UTP-Selective, and an ATP- and UTP-Specific Receptor, 224
- Nickenig, G., and Murphy, T. J. Enhanced Angiotensin Receptor Type 1 mRNA Degradation and Induction of Polyribosomal mRNA Binding Proteins by Angiotensin II in Vascular Smooth Muscle Cells, 743
- Nicoletti, F. *see* Thomsen, C., 6
- Nicosia, S. *see* Rovati, G. E., 86
- Nie, L., Mogami, H., Kanzaki, M., Shibata, H., and Kojima, I. Blockade of DNA Synthesis Induced by Platelet-Derived Growth Factor by Tranilast, an Inhibitor of Calcium Entry, in Vascular Smooth Muscle Cells, 763
- Nishigaki, N., Negishi, M., and Ichikawa, A. Two G<sub>q</sub>-Coupled Prostaglandin E Receptor Subtypes, EP2 and EP4, Differ in Desensitization and Sensitivity to the Metabolic Inactivation of the Agonist, 1031
- Nitecki, D. E. *see* Wu, J. M., 1355
- Nitiss, J. L., and Wang, J. C. Mechanisms of Cell Killing by Drugs that Trap Covalent Complexes between DNA Topoisomerases and DNA, 1095
- Norris, T. M., Moya, E., Blagbrough, I. S., and Adams, M. E. Block of High-Threshold Calcium Channels by the Synthetic Polyamines sFTX-3.3 and FTX-3.3, 939
- North, R. A. *see* Matthes, H., 447
- Nouet, S. *see* Chidiac, P., 662
- Nowak, M. W. *see* Kearney, P. C., 1401
- O**
- O'dowd, B. F. *see* Pak, Y., 1214
- Oksche, A., Schüle, R., Rutz, C., Liebenhoff, U., Dickson, J., Müller, H., Birnbaumer, M., and Rosenthal, W. Vasopressin V2 Receptor Mutants That Cause X-Linked Nephrogenic Diabetes Insipidus: Analysis of Expression, Processing, and Function, 820
- Olson, L. J., Lowe, D. G., and Drewett, J. G. Novel Natriuretic Peptide Receptor/Guanylyl Cyclase A-Selective Agonist Inhibits Angiotensin II- and Forskolin-Evoked Aldosterone Synthesis in a Human Zona Glomerulosa Cell Line, 430
- O'Neill, T. J. *see* Rogowski, R. S., 1167
- Onogi, T. *see* Minami, M., 1413
- Ordentlich, A. *see* Grosfeld, H., 639
- Oswald, R. E. *see* Wo, Z. G., 770
- Overman, L. E. *see* Ragozzino, D., 1024
- P**
- Paine, A. J. *see* Wright, M. C., 856
- Pak, Y., Kouvelas, A., Scheideler, M. A., Rasmussen, J., O'dowd, B. F., and George, S. R. Agonist-Induced Functional Desensitization of the  $\mu$ -Opioid Receptor Is Mediated by Loss of Membrane Receptors Rather than Uncoupling from G Protein, 1214
- Palmer, S. F. *see* Grigoriadis, D. E., 679
- Palumbo, E. M. M. *see* Sissi, C., 838
- Pampori, N. A., and Shapiro, B. H. Feminization of Hepatic Cytochrome P450s by Nominal Levels of Growth Hormone in the Feminine Plasma Profile, 1148
- Panti, S. *see* Perno, C.-F., 359
- Parmentier, M.-L. *see* Gomez, J., 923
- Parniak, M. A. *see* Arion, D., 1057
- Pascual, J. M. S. *see* Zeldin, D. C., 1111
- Pasternak, G. W. *see* Standifer, K. M., 293
- Patel, B. P. *see* Bass, R. T., 709
- Patel, S. *see* Patel, S., 1658
- Patel, S., Patel, S., Marwood, R., Emms, F., Marston, D., Leeson, P. D., Curtis, N. R., Kulagowski, J. J., and Freedman, S. B. Identification and Pharmacological Characterization of [<sup>125</sup>I]L-750,667, a Novel Radioligand for the Dopamine D<sub>4</sub> Receptor, 1658
- Pausch, M. H. *see* Bass, R. T., 709
- Pausch, M. H. *see* Price, L. A., 829
- Payet, M.-D. *see* Grazzini, E., 1273
- Peavy, R. D. *see* Theroux, T. L., 1376
- Pelemans, H. *see* Balzarini, J., 394
- Pellicciari, R. *see* Thomsen, C., 6
- Pelto-Huikko, M. *see* Hedlund, E., 342
- Pelzer, S. *see* Asai, T., 1262
- Perego, P., Jimenez, G., and Howell, S. B. Isolation and Characterization of a Cisplatin-Resistant Strain of *Schizosaccharomyces pombe*, 1080
- Perez, D. M. *see* Zhao, M.-M., 1118

- Perno, C.-F. *see* Balzarini, J., 394
- Perno, C.-F., Balestra, E., Aquaro, S., Panti, S., Cenci, A., Lazzarino, G., Tavazzi, B., Di Pierro, D., Balzarini, J., and Calò, R. Potent Inhibition of Human Immunodeficiency Virus and Herpes Simplex Virus Type 1 by 9-(2-Phosphonylmethoxyethyl)adenine in Primary Macrophages Is Determined by Drug Metabolism, Nucleotide Pools, and Cytokines, 359
- Peters, J. M., Zhou, Y.-C., Ram, P. A., Lee, S. S. T., Gonzalez, F. J., and Waxman, D. J. Peroxisome Proliferator-Activated Receptor  $\alpha$  Required for Gene Induction by Dehydroepiandrosterone-3 $\beta$ -sulfate, 67
- Petralia, S. *see* Cavallaro, S., 60
- Pichon, C. *see* Stewart, A. J., 1487
- Pimenta, M. *see* Wright, M. C., 856
- Pin, J.-P. *see* Gomez, J., 923
- Pin, J.-P. *see* McCool, B. A., 912
- Piros, E. T., Prather, P. L., Law, P. Y., Evans, C. J., and Hales, T. G. Voltage-Dependent Inhibition of Ca<sup>2+</sup> Channels in GH<sub>3</sub> Cells by Cloned  $\mu$ - and  $\delta$ -Opioid Receptors, 947
- Plantefol, M. *see* Massot, O., 752
- Polonsky, K. S. *see* Glaum, S. R., 230
- Pommier, Y. *see* Fujimori, A., 1472
- Post-Munson, D. J. *see* Gribkoff, V. K., 206
- Potenza, C. *see* Barwick, J. L., 10
- Potter, B. V. L. *see* Murphy, C. T., 1223
- Pouliot, J.-F. *see* Liu, Z., 482
- Poussu, K. *see* Hohenegger, M., 1443
- Poyner, D. R. *see* Coulson, J. M., 314
- Pratesi, G. *see* Animati, F., 603
- Prather, P. L. *see* Piros, E. T., 947
- Pratt, D. S. *see* Schmitz, F., 436
- Price, C. J., and Raymond, L. A. Evans Blue Antagonizes Both  $\alpha$ -Amino-3-hydroxy-5-methyl-4-isoxazolepropionate and Kainate Receptors and Modulates Receptor Desensitization, 1665
- Price, L. A. *see* Bass, R. T., 709
- Price, L. A., Strnad, J., Pausch, M. H., and Hadcock, J. R. Pharmacological Characterization of the Rat A<sub>2a</sub> Adenosine Receptor Functionally Coupled to the Yeast Pheromone Response Pathway, 829
- Probst, M. R. *see* Zhang, J., 1454
- Prudhomme, N. *see* Massot, O., 752
- Puel, J. *see* Mesange, F., 75
- Pulaski, J. T. *see* Jeon, Y. J., 334
- Putney, J. W., Jr. *see* Lobaugh, L. A., 493
- Q**
- Quattrocchi, L. C. *see* Barwick, J. L., 10
- Quillan, J. M. *see* Alvaro, J. D., 583
- R**
- Rabkin, S. D. *see* Yazaki, T., 236
- Ragozzino, D., Woodward, R. M., Murata, Y., Eusebi, F., Overman, L. E., and Miledi, R. Design and *In Vitro* Pharmacology of a Selective  $\gamma$ -Aminobutyric Acid<sub>C</sub> Receptor Antagonist, 1024
- Ram, P. A. *see* Peters, J. M., 67
- Ramamoorthy, L., Kemp, M. C., and Tizard, I. R. Acemannan, a  $\beta$ -(1,4)-Acetylated Mannan, Induces Nitric Oxide Production in Macrophage Cell Line RAW 264.7, 878
- Ramamoorthy, S. *see* Melikian, H. E., 266
- Rando, R. R. *see* Xu, Y., 1495
- Rasmussen, J. *see* Pak, Y., 1214
- Rauer, H. *see* Nguyen, A., 1672
- Rauer, H., and Grissmer, S. Evidence for an Internal Phenylalkylamine Action on the Voltage-Gated Potassium Channel Kv1.3, 1625
- Raymond, L. A. *see* Price, C. J., 1665
- Reinecke, M. G. *see* Robinson, W. E., Jr., 846
- Restituto, S. *see* Gomez, J., 923
- Reszka, K. J., and Chignell, C. F. Acid-Catalyzed Oxidation of the Anticancer Agent Mitoxantrone by Nitrite Ions, 1612
- Rhee, A. M. V. *see* Jiang, Q., 512
- Ribeiro, V. *see* Wright, M. C., 856
- Rice, K. *see* Varga, E. V., 1619
- Riley, A. M. *see* Murphy, C. T., 1223
- Ritzel, M. W. L. *see* Yao, S. Y. M., 1529
- Rivkees, S. A. *see* Barbhuiya, H., 1635
- Robberecht, P. *see* Van Rampelbergh, J., 1596
- Robbins, J. D. *see* Sutkowski, E. M. H., 299
- Roberts, L. J. *see* Itoh, S., 736
- Robinson, C. E. *see* Gimble, J. M., 1087
- Robinson, W. E., Jr., Cordeiro, M., Abdel-Malek, S., Jia, Q., Chow, S. A., Reinecke, M. G., and Mitchell, W. M. Dicafeoylquinic Acid Inhibitors of Human Immunodeficiency Virus Integrase: Inhibition of the Core Catalytic Domain of Human Immunodeficiency Virus Integrase, 846
- Roche, A. C. *see* Stewart, A. J., 1487
- Rodriguez, B. R. *see* Gimble, J. M., 1087
- Roeske, W. R. *see* Varga, E. V., 1619
- Rogawski, M. A. *see* Rogowski, R. S., 1167
- Rogowski, R. S., Collins, J. H., O'Neill, T. J., Gustafson, T. A., Werkman, T. R., Rogawski, M. A., Tenenholz, T. C., Weber, D. J., and Blaustein, M. P. Three New Toxins from the Scorpion *Pandinus imperator* Selectively Block Certain Voltage-Gated K<sup>+</sup> Channels, 1167
- Romero-Avila, T. *see* Boyer, J. L., 1323
- Romine, J. L. *see* Gribkoff, V. K., 206
- Rosenthal, W. *see* Oksche, A., 820
- Ross, D. *see* Gustafson, D. L., 728
- Ross, D. *see* Moran, J. L., 610
- Rosser, D. *see* Tew, K. D., 149
- Rossi, G. C. *see* Standifer, K. M., 293
- Roth, B. L. *see* Berry, S. A., 306
- Rousseau, B. *see* Massot, O., 752
- Rousselle, J.-C. *see* Massot, O., 752
- Rovati, G. E., Shrager, R., Nicosia, S., and Munson, P. J. KINFIT II: A Nonlinear Least-Squares Program for Analysis of Kinetic Binding Data, 86
- Rowe, T. C. *see* Lawrence, J. W., 1178
- Rowlands, J. C., McEwan, I. J., and Gustafsson, J.-A. *Trans*-activation by the Human Aryl Hydrocarbon Receptor and Aryl Hydrocarbon Receptor Nuclear Translocator Proteins: Direct Interactions with Basal Transcription Factors, 538
- Ruan, Y. *see* Kan, H., 1139
- Ruble, J. *see* Srinivas, M., 196
- Rudolf, K. *see* Sautel, M., 285
- Rümenapp, U. *see* Schmidt, M., 1038
- Rutz, C. *see* Oksche, A., 820
- Ryu, D.-Y., Levi, P. E., Fernandez-Salguero, P., Gonzalez, F. J., and Hodgson, E. Piperonyl Butoxide and Acenaphthylene Induce Cytochrome P450 1A2 and 1B1 mRNA in Aromatic Hydrocarbon-Responsive Receptor Knock-Out Mouse Liver, 443
- S**
- Sadeghi, H. *see* Innamorati, G., 467
- Salvatore, C. *see* Animati, F., 603
- Sanders-Bush, E. *see* Canton, H., 799
- Sarközi, S. *see* Hohenegger, M., 1443
- Satoh, M. *see* Minami, M., 1413
- Saulnier-Blache, J. S., Yang, Q., Sherlock, J. D., and Lanier, S. M. Analysis of the  $\alpha_2C$ -Adrenergic Receptor Gene Promoter and Its Cell-Type-Specific Activity, 1432
- Sausen, P. J. *see* Corton, J. C., 1157

- Sautel, M., Rudolf, K., Wittneben, H., Herzog, H., Martinez, R., Munoz, M., Eberlein, W., Engel, W., Walker, P., and Beck-Sicking, A. G. Neuropeptide Y and the Nonpeptide Antagonist BIBP 3226 Share an Overlapping Binding Site at the Human Y<sub>1</sub> Receptor, 285
- Scammells, P. J. *see* Srinivas, M., 196
- Schachter, J. B. *see* Boyer, J. L., 1323
- Scheideler, M. A. *see* Pak, Y., 1214
- Schermerhorn, T. *see* Komatsu, M., 1047
- Scheuer, T. *see* Johnson, B. D., 1387
- Scheurer, L. *see* Knoflach, F., 1253
- Schmidt, D. E., Jr. *see* Tew, K. D., 149
- Schmidt, K. *see* Schrammel, A., 1
- Schmidt, M. *see* Zhang, C., 864
- Schmidt, M., Nehls, C., Rumenapp, U., and Jakobs, K. H. m3 Muscarinic Receptor-Induced and G<sub>i</sub>-Mediated Heterologous Potentiation of Phospholipase C Stimulation: Role of Phosphoinositide Synthesis, 1038
- Schmidt, R. R. *see* Berger, A., 451
- Schmieden, V., Jezequel, S., and Betz, H. Novel Antagonists of the Inhibitory Glycine Receptor Derived from Quinolinic Acid Compounds, 1200
- Schmitz, F., Pratt, D. S., Wu, M.-J., Kolakowski, L. F., Jr., Beinborn, M., and Kopin, A. S. Identification of Cholecystokinin-B/Gastrin Receptor Domains that Confer High Gastrin Affinity: Utilization of a Novel *Xenopus laevis* Cholecystokinin Receptor, 436
- Schober, D. A. *see* Gehlert, D. R., 112
- Schofield, P. R. *see* Mascia, M. P., 402
- Schols, D. *see* Balzarini, J., 394
- Schonbrunn, A. *see* Williams, B. Y., 716
- Schotte, A. *see* Leysen, J. E., 1567
- Schrammel, A., Behrends, S., Schmidt, K., Koesling, D., and Mayer, B. Characterization of 1*H*-[1,2,4]Oxadiazolo[4,3-*a*]quinoxalin-1-one as a Heme-Site Inhibitor of Nitric Oxide-Sensitive Guanylyl Cyclase, 1
- Schüle, R. *see* Oksche, A., 820
- Schuster, V. L. *see* Itoh, S., 736
- Schwartz, T. W. *see* Hjorth, S. A., 977
- Scribner, M. K. *see* Wade, S. M., 351
- Sealfon, S. C. *see* Alaula, N., 34
- Seamon, K. B. *see* Sutkowski, E. M. H., 299
- Séguéla, P. *see* Bouchélet, I., 219
- Seguin, L. *see* Massot, O., 752
- Seki, T. *see* Minami, M., 1413
- Selander, K. S., Mönkkönen, J., Karhukorpi, E.-K., Härkönen, P., Hannuniemi, R., and Väänänen, H. K. Characteristics of Clodronate-Induced Apoptosis in Osteoclasts and Macrophages, 1127
- Seward, E. P. *see* Matthes, H., 447
- Shafferman, A. *see* Grosfeld, H., 639
- Shah, M. C. *see* Berry, S. A., 306
- Shapiro, B. H. *see* Pampori, N. A., 1148
- Sharp, G. W. G. *see* Komatsu, M., 1047
- Sherlock, J. D. *see* Saulnier-Blache, J. S., 1432
- Shibata, H. *see* Nie, L., 763
- Shrager, R. *see* Rovati, G. E., 86
- Shreeve, S. M. *see* Diehl, N. L., 624
- Shryock, J. C. *see* Srinivas, M., 196
- Siegel, D. *see* Moran, J. L., 610
- Sikela, J. *see* Wafford, K. A., 670
- Silverman, S. K. *see* Kearney, P. C., 1401
- Simmons, M. L., and Chavkin, C.  $\kappa$ -Opioid Receptor Activation of a Dendrotoxin-Sensitive Potassium Channel Mediates Presynaptic Inhibition of Mossy Fiber Neurotransmitter Release, 80
- Simon, J. *see* Webb, T. E., 258
- Sissi, C., Capranico, G., and Palumbo, E. M. M. Aza-bioisosteres of 9,10-anthracenedione: A Modulation of DNA Sequence Specificity, 838
- Sivertsen, S. *see* Handel, M. L., 501
- Smiley, D. L. *see* Gehlert, D. R., 112
- Soreq, H. *see* Loewenstein-Lichtenstein, Y., 1423
- Spiegel, S. *see* Berger, A., 451
- Srinivas, M., Shryock, J. C., Scammells, P. J., Ruble, J., Baker, S. P., and Belardinelli, L. A Novel Irreversible Antagonist of the A<sub>1</sub>-Adenosine Receptor, 196
- Stadel, J. M. *see* Wong, A., 529
- Standifer, K. M., Rossi, G. C., and Pasternak, G. W. Differential Blockade of Opioid Analgesia by Antisense Oligodeoxynucleotides Directed against Various G Protein  $\alpha$  Subunits, 293
- Starmer, C. F. *see* Grant, A. O., 1643
- Starrett, J. E., Jr. *see* Gribkoff, V. K., 206
- Steenbergen, C. *see* Zeldin, D. C., 1111
- Stefanovic, B. *see* Iimuro, Y., 656
- Steinbach, J. H. *see* Ueno, S., 931
- Sternfeld, M. *see* Loewenstein-Lichtenstein, Y., 1423
- Stevens, J. L. *see* Jeong, J. K., 592
- Stewart, A. J., Pichon, C., Meunier, L., Midoux, P., Monsigny, M., and Roche, A. C. Enhanced Biological Activity of Antisense Oligonucleotides Complexed with Glycosylated Poly-L-lysine, 1487
- Stivala, F. *see* Cavallaro, S., 60
- Strange, P. G. *see* Hoare, S. R. J., 1295
- Straub, S. G. *see* Komatsu, M., 1047
- Strnad, J. *see* Bass, R. T., 709
- Strnad, J. *see* Price, L. A., 829
- Stropova, D. *see* Varga, E. V., 1619
- Suh-Kim, H., Wei, X., and Birnbaumer, L. Subunit Composition Is a Major Determinant in High Affinity Binding of a Ca<sup>2+</sup> Channel Blocker, 1330
- Sun, X.-M. *see* Moran, J. L., 610
- Sun, Y. *see* Conklin, B. R., 885
- Supino, R. *see* Animati, F., 603
- Sutherland, R. L. *see* Handel, M. L., 501
- Sutkowski, E. M. H., Robbins, J. D., Tang, W.-J., and Seamon, K. B. Irreversible Inhibition of Forskolin Interactions with Type I Adenylate Cyclase by a 6-Isothiocyanate Derivative of Forskolin, 299
- Swain, C. J. *see* Fong, T. M., 1605
- Swords, B. *see* Liliom, K., 616
- Szabo, G. *see* Magyar, J., 1520

## T

- Tabakoff, B. *see* Yoshimura, M., 43
- Tang, W.-J. *see* Sutkowski, E. M. H., 299
- Tashjian, A. H., Jr. *see* Xu, Y., 1495
- Tate, C. G. *see* Melikian, H. E., 266
- Tatro, J. B. *see* Alvaro, J. D., 583
- Tavazzi, B. *see* Perno, C.-F., 359
- Taylor, C. W. *see* Hargreaves, A. C., 1284
- Taylor, J. M. *see* Wade, S. M., 351
- Taylor, L. P. *see* Cho, W., 1338
- Tenenholz, T. C. *see* Rogowski, R. S., 1167
- Terwilliger, R. *see* Iredale, P. A., 1103
- Tew, K. D., Monks, A., Barone, L., Rosser, D., Akerman, G., Montali, J. A., Wheatley, J. B., and Schmidt, D. E., Jr. Glutathione-Associated Enzymes in the Human Cell Lines of the National Cancer Institute Drug Screening Program, 149
- Theroux, T. L., Esbenshade, T. A., Peavy, R. D., and Minneman, K. P. Coupling Efficiencies of Human  $\alpha_1$ -Adrenergic Receptor Subtypes: Titration of Receptor Density and Responsiveness with Inducible and Repressible Expression Vectors, 1376
- Thirstrup, K. *see* Hjorth, S. A., 977
- Thomas, D. *see* Wafford, K. A., 670
- Thompson, S. A. *see* Wafford, K. A., 670
- Thomsen, C., Bruno, V., Nicoletti, F., Marinozzi, M., and Pellicciari, R. (2*S*,1'*S*,2'*S*,3'*R*)-2-(2'-Carboxy-3'-phenylcyclopropyl)glycine,

- a Potent and Selective Antagonist of Type 2 Metabotropic Glutamate Receptors, 6
- Thormar, H. *see* Balzarini, J., 1207
- Thurman, R. G. *see* Iimuro, Y., 656
- Tietz, E. I. *see* Burgard, E. C., 119
- Tigyi, G. *see* Liliom, K., 616
- Tindberg, N., Baldwin, H. A., Cross, A. J., and Ingelman-Sundberg, M. Induction of Cytochrome P450 2E1 Expression in Rat and Gerbil Astrocytes by Inflammatory Factors and Ischemic Injury, 1065
- Tinelli, S. *see* Cornarotti, M., 1463
- Tivel, K. L. *see* Alahari, S. K., 808
- Tizard, I. R. *see* Ramamoorthy, L., 878
- Tohkin, M., Kurose, K., and Fukuhara, M. Okadaic Acid Potentiates 3-Methylcholanthrene-Induced CYP2A8 Gene Expression in Primary Cultures of Syrian Hamster Hepatocytes: Possible Involvement of AP-1, 556
- Tomer, K. B. *see* Zeldin, D. C., 1111
- Torphy, T. J. *see* Jacobitz, S., 891
- Torres, G. E., Arfken, C. L., and Andrade, R. 5-Hydroxytryptamine<sub>1</sub> Receptors Reduce Afterhyperpolarization in Hippocampus by Inhibiting Calcium-Induced Calcium Release, 1316
- Travali, S. *see* Cavallaro, S., 60
- Trial, J. *see* Morrison, K. J., 692
- Trojnacki, J. T. *see* Gribkoff, V. K., 206
- True, C. D. *see* Grigoriadis, D. E., 679
- Trueba, M. *see* Azula, F. J., 367
- Tseng, C.-P., and Verma, A. K. Inhibition of 12-*O*-Tetradecanoylphorbol-13-acetate-Induced Ornithine Decarboxylase Activity by Genistein, a Tyrosine Kinase Inhibitor, 249
- Tsyganskaya, M. *see* Glascott, P. A., Jr., 994
- Tukey, R. H. *see* Barwick, J. L., 10
- Tuvim, M. *see* Morrison, K. J., 692
- U**
- Ueno, S., Zorumski, C., Bracamontes, J., and Steinbach, J. H. Endogenous Subunits Can Cause Ambiguities in the Pharmacology of Exogenous  $\gamma$ -Aminobutyric Acid<sub>A</sub> Receptors Expressed in Human Embryonic Kidney 293 Cells, 931
- V**
- Väänänen, H. K. *see* Selander, K. S., 1127
- Vahlenkamp, T. *see* Balzarini, J., 1207
- Vale, W. W. *see* Grigoriadis, D. E., 679
- Valenzuela, C. F. *see* Mascia, M. P., 402
- Vandenbranden, M. *see* Haehner, B. D., 52
- Van De Weyer, I. *see* Leysen, J. E., 1567
- Van Gompel, P. *see* Leysen, J. E., 1567
- Vanhoenacker, P. *see* Leysen, J. E., 1567
- Van Koppen, C. J. *see* Bogatkewitsch, G. S., 424
- Van Rampelbergh, J., Gourlet, P., De Neef, P., Robberecht, P., and Waelbroeck, M. Properties of the Pituitary Adenylate Cyclase-Activating Polypeptide I and II Receptors, Vasoactive Intestinal Peptide<sub>1</sub>, and Chimeric Amino-Terminal Pituitary Adenylate Cyclase-Activating Polypeptide/Vasoactive Intestinal Peptide<sub>1</sub> Receptors: Evidence for Multiple Receptor States, 1596
- Varga, E. V., Li, X., Stropova, D., Zalewska, T., Landsman, R. S., Knapp, R. J., Malatynska, E., Kawai, K., Mizusura, A., Nagase, H., Calderon, S. N., Rice, K., Hruby, V. J., Roeske, W. R., and Yamamura, H. I. The Third Extracellular Loop of the Human  $\delta$ -Opioid Receptor Determines the Selectivity of  $\delta$ -Opioid Agonists, 1619
- Vasey, P. A., Jones, N. A., Jenkins, S., Dive, C., and Brown, R. Cisplatin, Camptothecin, and Taxol Sensitivities of Cells with p53-Associated Multidrug Resistance, 1536
- Vaughn, J. *see* Grigoriadis, D. E., 679
- Vázquez-Prado, J., and García-Sáinz, J. A. Effect of Phorbol Myristate Acetate on  $\alpha_1$ -Adrenergic Action in Cells Expressing Recombinant  $\alpha_1$ -Adrenoceptor Subtypes, 17
- Velan, B. *see* Grosfeld, H., 639
- Ventra, C. *see* Cavallaro, S., 60
- Verma, A. K. *see* Tseng, C.-P., 249
- Vicini, S. *see* Zhu, W. J., 23
- Vissel, B. *see* Krupp, J. J., 1680
- von Eichel-Streiber, C. *see* Zhang, C., 864
- Voyno-Yasenetskaya, T. A. *see* Conklin, B. R., 885
- W**
- Wa, R. M. *see* Whittemore, E. R., 1364
- Wade, S. M., Scribner, M. K., Dalman, H. M., Taylor, J. M., and Neubig, R. R. Structural Requirements for G<sub>o</sub> Activation by Receptor-Derived Peptides: Activation and Modulation Domains of the  $\alpha_2$ -Adrenergic Receptor i3c Region, 351
- Waelbroeck, M. *see* Van Rampelbergh, J., 1596
- Wafford, K. A., Thompson, S. A., Thomas, D., Sikela, J., Wilcox, A. S., and Whiting, P. J. Functional Characterization of Human  $\gamma$ -Aminobutyric Acid<sub>A</sub> Receptors Containing the  $\alpha_4$  Subunit, 670
- Waldren, C. A. *see* Gustafson, D. L., 728
- Walker, P. *see* Sautel, M., 285
- Wang, J. C. *see* Nitiss, J. L., 1095
- Wang, J. F. *see* Zhu, W. J., 23
- Wang, S. *see* Webb, T. E., 258
- Wang, X., and Horisberger, J.-D. Mercury Binding Site on Na<sup>+</sup>/K<sup>+</sup>-ATPase: A Cysteine in the First Transmembrane Segment, 687
- Wang, X.-J. *see* Wright, M. C., 856
- Wang, Y. *see* Knoflach, F., 1253
- Wang, Y. *see* Williams, B. Y., 716
- Ward, S. A. *see* Bray, P. G., 1551, 1559
- Warner, M. *see* Hedlund, E., 342
- Watkins, P. B. *see* Haehner, B. D., 52
- Watson, A. J. *see* Zhang, J., 1454
- Watt, W. C. *see* Nicholas, R. A., 224
- Watts, C. K. W. *see* Handel, M. L., 501
- Watts, V. J., and Neve, K. A. Sensitization of Endogenous and Recombinant Adenylate Cyclase by Activation of D<sub>2</sub> Dopamine Receptors, 966
- Waxman, D. J. *see* Peters, J. M., 67
- Webb, T. E., Henderson, D., King, B. F., Wang, S., Simon, J., Bateson, A. N., Burnstock, G., and Barnard, E. A. A Novel G Protein-Coupled P<sub>2</sub> Purinoceptor (P<sub>2Y3</sub>) Activated Preferentially by Nucleoside Diphosphates, 258
- Weber, D. J. *see* Rogowski, R. S., 1167
- Weber, E. *see* Ilyin, V. I., 1541
- Wei, X. *see* Suh-Kim, H., 1330
- Weight, F. F. *see* Yu, D., 1010
- Weinstein, H. *see* Almula, N., 34
- Weissig, V. *see* Lawrence, J. W., 1178
- Wells, J. N. *see* Kennedy, A. P., 789
- Werkman, T. R. *see* Rogowski, R. S., 1167
- Wess, J. *see* Jiang, Q., 512
- Westbrook, G. L. *see* Krupp, J. J., 1680
- Westwick, J. *see* Murphy, C. T., 1223
- Wheatley, J. B. *see* Tew, K. D., 149
- Whiting, P. J. *see* Wafford, K. A., 670
- Whittemore, E. R. *see* Ilyin, V. I., 1541
- Whittemore, E. R., Yang, W., Drewe, J. A., and Wa, R. M. Pharmacology of the Human  $\gamma$ -Aminobutyric Acid<sub>A</sub> Receptor  $\alpha_4$  Subunit Expressed in *Xenopus laevis* Oocytes, 1364
- Wible, B. *see* Kiehn, J., 380
- Widnell, K. L. *see* Iredale, P. A., 1103
- Wilcox, A. S. *see* Wafford, K. A., 670

- Williams, B. Y., Wang, Y., and Schonbrunn, A. Agonist Binding and Protein Kinase C Activation Stimulate Phosphorylation of the Gastrin-Releasing Peptide Receptor at Distinct Sites, 716
- Williams, K., Chao, J., Kashiwagi, K., Masuko, T., and Igarashi, K. Activation of *N*-Methyl-D-Aspartate Receptors by Glycine: Role of an Aspartate Residue in the M3-M4 Loop of the NR1 Subunit, 701
- Willmore, E. *see* Cornarotti, M., 1463
- Witt-Enderby, P. A., and Dubocovich, M. L. Characterization and Regulation of the Human ML<sub>1A</sub> Melatonin Receptor Stably Expressed in Chinese Hamster Ovary Cells, 166
- Wittmer, L. L., Hu, Y., Kalkbrenner, M., Evers, A. S., Zorumski, C. F., and Covey, D. F. Enantioselectivity of Steroid-Induced  $\gamma$ -Aminobutyric Acid<sub>A</sub> Receptor Modulation and Anesthesia, 1581
- Wittneben, H. *see* Sautel, M., 285
- Witvrouw, M. *see* Balzarini, J., 394
- Wo, Z. G., and Oswald, R. E. Ligand-Binding Characteristics and Related Structural Features of the Expressed Goldfish Kainate Receptors: Identification of a Conserved Disulfide Bond and Three Residues Important for Ligand Binding, 770
- Wong, A., Hwang, S. M., Mcdevitt, P., McNulty, D., Stadel, J. M., and Johanson, K. Studies on  $\alpha_2\beta_2$ /Ligand Interactions Using a [<sup>3</sup>H]SK&F-107260 Binding Assay, 529
- Wong, Y. H. *see* Chiu, T. T., 1651
- Woodward, R. M. *see* Ilyin, V. I., 1541
- Woodward, R. M. *see* Ragazzino, D., 1024
- Wouters, R. *see* Leysen, J. E., 1567
- Wright, M. C., Wang, X.-J., Pimenta, M., Ribeiro, V., Paine, A. J., and Lechner, M. C. Glucocorticoid Receptor-Independent Transcriptional Induction of Cytochrome P450 3A1 by Metyrapone and its Potentiation by Glucocorticoid, 856
- Wrighton, S. A. *see* Haehner, B. D., 52
- Wu, J. M. *see* Feldman, R. I., 1346
- Wu, J. M., Nitecki, D. E., Biancalana, S., and Feldman, R. I. Discovery of High Affinity Bombesin Receptor Subtype 3 Agonists, 1355
- Wu, M.-J. *see* Schmitz, F., 436
- Wu, S. *see* Zeldin, D. C., 1111
- Wu, X. *see* Gimble, J. M., 1087
- Wyatt, R. J. *see* Masserano, J. M., 1309
- Wyss, A. *see* Hedlund, E., 342
- X**
- Xu, Y., Gilbert, B. A., Rando, R. R., Chen, L., and Tashjian, A. H., Jr. Inhibition of Capacitative Ca<sup>2+</sup> Entry into Cells by Farnesylcysteine Analogs, 1495
- Y**
- Yamamura, H. I. *see* Varga, E. V., 1619
- Yang, C.-M. *see* Yu, S.-M., 1000
- Yang, K.-H. *see* Jeon, Y. J., 334
- Yang, Q. *see* Saulnier-Blache, J. S., 1432
- Yang, W. *see* Whittemore, E. R., 1364
- Yao, S. Y. M., Cass, C. E., and Young, J. D. Transport of the Antiviral Nucleoside Analogs 3'-Azido-3'-deoxythymidine and 2',3'-Dideoxycytidine by a Recombinant Nucleoside Transporter (rCNT1) Expressed in *Xenopus laevis* Oocytes, 388
- Yao, S. Y. M., Ng, A. M. L., Ritzel, M. W. L., Gati, W. P., Cass, C. E., and Young, J. D. Transport of Adenosine by Recombinant Purine- and Pyrimidine-Selective Sodium/Nucleoside Cotransporters from Rat Jejunum Expressed in *Xenopus laevis* Oocytes, 1529
- Yasuda, H. *see* Figler, R. A., 1587
- Yazaki, T., Ahmad, S., Chahlavi, A., Zylber-Katz, E., Dean, N. M., Rabkin, S. D., Martuza, R. L., and Glazer, R. I. Treatment of Glioblastoma U-87 by Systemic Administration of an Antisense Protein Kinase C- $\alpha$  Phosphorothioate Oligodeoxynucleotide, 236
- Yehle, S. *see* Jiang, Q., 512
- Yoshimura, M., Ikeda, H., and Tabakoff, B.  $\mu$ -Opioid Receptors Inhibit Dopamine-Stimulated Activity of type V Adenylyl Cyclase but Enhance Dopamine-Stimulated Activity of type VII Adenylyl Cyclase, 43
- Young, J. D. *see* Yao, S. Y. M., 1529, 388
- Yu, D., Zhang, L., Eiselé, J.-L., Bertrand, D., Changeux, J.-P., and Weight, F. F. Ethanol Inhibition of Nicotinic Acetylcholine Type  $\alpha 7$  Receptors Involves the Amino-Terminal Domain of the Receptor, 1010
- Yu, H. *see* Fong, T. M., 1605
- Yu, H., Cai, J. J., and Lee, H.-C. Cyclic AMP-Dependent Phosphodiesterase Isozyme-Specific Potentiation by Protein Kinase C in Hypertrophic Cardiomyopathic Hamster Hearts, 549
- Yu, S.-M., Chen, S.-F., Lau, Y.-T., Yang, C.-M., and Chen, J.-C. Mechanism of Extracellular ATP-Induced Proliferation of Vascular Smooth Muscle Cells, 1000
- Yung, L. Y. *see* Chiu, T. T., 1651
- Z**
- Zakut, H. *see* Loewenstein-Lichtenstein, Y., 1423
- Zalewska, T. *see* Varga, E. V., 1619
- Zeldin, D. C., Foley, J., Ma, J., Boyle, J. E., Pascual, J. M. S., Moomaw, C. R., Tomer, K. B., Steenbergen, C., and Wu, S. CYP2J Subfamily P450s in the Lung: Expression, Localization, and Potential Functional Significance, 1111
- Zern, M. A. *see* Glascott, P. A., Jr., 994
- Zhang, C., Schmidt, M., von Eichel-Streiber, C., and Jakobs, K. H. Inhibition by Toxin B of Inositol Phosphate Formation Induced by G Protein-Coupled and Tyrosine Kinase Receptors in N1E-115 Neuroblastoma Cells: Involvement of Rho Proteins, 864
- Zhang, J., Watson, A. J., Probst, M. R., Minehart, E., and Hankinson, O. Basis for the Loss of Aryl Hydrocarbon Receptor Gene Expression in Clones of a Mouse Hepatoma Cell Line, 1454
- Zhang, L. *see* Yu, D., 1010
- Zhao, M.-M., Hwa, J., and Perez, D. M. Identification of Critical Extracellular Loop Residues Involved in  $\alpha_1$ -Adrenergic Receptor Subtype-Selective Antagonist Binding, 1118
- Zhong, H., Guerrero, S. W., Esbenshade, T. A., and Minneman, K. P. Inducible Expression of  $\beta_1$ - and  $\beta_2$ -Adrenergic Receptors in Rat C<sub>6</sub> Glioma Cells: Functional Interactions between Closely Related Subtypes, 175
- Zhong, J. *see* Gribkoff, V. K., 206
- Zhong, J., Gribkoff, V. K., and Molinoff, P. B. Use of Subunit-Specific Antisense Oligodeoxynucleotides to Define Developmental Changes in the Properties of *N*-Methyl-D-aspartate Receptors, 631
- Zhong, W. *see* Kearney, P. C., 1401
- Zhou, Y.-C. *see* Peters, J. M., 67
- Zhu, D., Cardenas, M. E., and Heitman, J. Calcineurin Mutants Render T Lymphocytes Resistant to Cyclosporin A, 506
- Zhu, W. J., Wang, J. F., Vicini, S., and Grayson, D. R.  $\alpha 6$  and  $\gamma 2$  Subunit Antisense Oligodeoxynucleotides Alter  $\gamma$ -Aminobutyric Acid Receptor Pharmacology in Cerebellar Granule Neurons, 23
- Zhuo, X. *see* Liu, C., 781
- Zioudrou, C. *see* Merkouris, M., 985
- Zorumski, C. *see* Ueno, S., 931
- Zorumski, C. F. *see* Wittmer, L. L., 1581
- Zunino, F. *see* Animati, F., 603
- Zunino, F. *see* Cornarotti, M., 1463
- Zylber-Katz, E. *see* Yazaki, T., 236

## SUBJECT INDEX FOR VOLUME 50

## A

- Acemannan, nitric oxide production induced by, in macrophage (mouse), 878
- Acenaphthylene, *CYP1A1* and *CYP1A2* induction by, in hepatic aromatic hydrocarbon-responsive receptor (mouse), 443
- Acetylcholine, prostacyclin synthesis induced by, in coronary endothelial cells (rabbit), 1139
- Acetylcholine receptor, *see* Muscarinic acetylcholine receptor; Nicotinic acetylcholine receptor
- Acetylcholinesterase mutant, phosphorylated, reactivation of (human), 639
- Activator protein-1  
activation of, sphingosylphosphocholine and sphingosine 1-phosphate and (rat), 451  
DNA binding by, penicillamine and (human), 501
- Adenosine, Na<sup>+</sup>-dependent transport of (rat, *Xenopus*), 1529
- Adenosine monophosphate, cyclic, *see* Cyclic adenosine monophosphate
- Adenosine receptor  
covalent modification of (bovine), 789  
G proteins and (bovine), 1587  
ligand recognition in (human), 512  
mutagenesis of (human), 1635  
yeast pheromone response pathway coupled to, pharmacologic characterization of (rat), 829
- Adenosine triphosphate, vascular smooth muscle cell proliferation induced by (rat), 1000
- Adenylate cyclase, dopamine receptor sensitization of (human), 966
- Adenylyl cyclase  
activation of, and ICI-174,864 effect on  $\delta$ -opioid receptor (human), 1651  
forskolin interaction with, isothiocyanate derivative of forskolin and (Sf9 cell), 299  
opioid receptor activity and (mouse), 43  
opioid receptor-mediated inhibition of, in smooth muscle (guinea pig), 870
- Adipogenesis, in bone marrow stromal cell, thiazolidinedione induction of (mouse), 1087
- $\alpha_1$ -Adrenergic receptor  
coupling efficiency of (human), 1376  
FSCPX as irreversible antagonist of, 196  
PD81,723 effects on (hamster, human), 104  
subtypes of, PMA and (rat), 17
- $\alpha_1$ -Adrenergic receptor antagonist, binding of (hamster, rat), 1118
- $\alpha_2$ -Adrenergic receptor  
activator region for (porcine), 351  
phospholipase C activated by, in renal epithelial cell (mouse), 407
- $\alpha_{2A}$ -Adrenergic receptor, signaling pathways of, secretion regulation by (mouse), 97
- $\alpha_{2A}$ -Adrenergic receptor gene, promoter elements of (rat), 1432
- $\beta_1$ - and  $\beta_2$ -Adrenergic receptor, in glioma cell (rat), 175
- $\beta_2$ -Adrenergic receptor  
agonist-induced up-regulation of, in neuroblastoma x glioma hybrid cell (human), 1479  
inverse agonist efficacy at (Sf9 cell), 662  
trafficking kinetics of (human), 692
- Agonist, CRF receptor regulation by (rat), 1103
- Alcohol, chronic exposure to, pancreatic  $\alpha$ -hydroxyethyl free radical adducts after (rat), 656
- Aldosterone synthesis, guanylyl cyclase A-selective agonist inhibition of (human), 430
- Alniditan, 5-hydroxytryptamine receptor binding of (bovine, human), 1567
- Alprenolol,  $\beta_2$ -adrenergic receptor up-regulation by, in neuroblastoma x glioma hybrid cell (human), 1479
- Amiloride, dopamine receptor regulation by (rat), 1295
- Amino acid(s), unnatural, at agonist binding site of nicotinic acetylcholine receptor (*Xenopus*), 1401
- $\gamma$ -Aminobutyric acid receptor  
cerebellar, furosemide and (rat), 23  
in dentate granule cell (rat), 458  
diazepam-insensitive recombinant, pharmacological modulation of (human), 1253  
pharmacology of  
in human, 931  
in *Xenopus*, 670  
protein kinase C modulation of (bovine), 185  
recombinant  $\alpha 5$  subtype-containing, (mouse), 119  
steroid enantiomers and (rat), 1581
- $\gamma$ -Aminobutyric acid receptor antagonist, pharmacology of (rat), 1024
- $\alpha$ -Amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor, Evans blue as antagonist for (human), 1665
- 4-Aminoquinoline resistance, of *Plasmodium falciparum*, 1551
- AMPA receptor, *see*  $\alpha$ -Amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor
- Analgesia, opioid, G proteins and (mouse), 293
- Anesthesia, steroid-induced, GABA<sub>A</sub> receptors and (rat), 1581
- Anesthetics, volatile, G protein-regulated muscarinic K<sup>+</sup> channel and (bullfrog), 1520
- Angiotensin II, aldosterone synthesis evoked by, guanylyl cyclase A-selective agonist inhibition of (human), 430
- Angiotensin II receptor, signaling pathway of (hamster), 522
- Angiotensin receptor-binding protein, in vascular smooth muscle cell (rat), 743
- Anthracenedione, aza-bioisosteres of (human), 838
- Anthracycline, biochemistry and pharmacology of (human), 603
- Antidepressant, tricyclic, serotonin transporter interaction with, phenylalanine 586 in (human), 957
- Antiestrogen, anti-HIV effects of (human), 75
- Antioxidant, vitamin C as (rat), 994
- Apoptosis  
of bone marrow progenitor cell, benzene metabolite induction of (human), 610  
of central nervous system catecholaminergic cell, dopamine induction of (mouse), 1309  
neuronal, PACAP receptor and (rat), 60  
of osteoclasts and macrophages, clodronate induction of (rat), 1127  
of T lymphocyte, p53 and (rat), 900
- AP-1, *see* Activator protein-1
- Arachidonic acid metabolism, 5-hydroxytryptamine receptor activation and (hamster), 1017
- Aromatic hydrocarbon-responsive receptor, in liver, and piperonyl butoxide and acenaphthylene induction of *CYP1A1* and *CYP1A2* (mouse), 443
- Aryl hydrocarbon receptor  
loss of gene for, in hepatoma cell (mouse), 1454  
*trans*-activation by (human), 538
- Astrocyte, CYP2E1 protein induction in, by inflammatory factors and ischemic injury (gerbil, rat), 1065

- Astrocytoma cell, uridine nucleotide receptors in (human), 224  
 Autoimmune hepatitis, *CYP2C9* gene epitope mapping in (human, rabbit), 326  
 Azidodeoxythymidine, transport of (*Xenopus*), 388

## B

- Baculovirus, *CYP2A3* and *CYP2A6* expression mediated by, olfactory toxicity and (rat, human), 781  
 Benzene metabolite, bone marrow progenitor cell apoptosis and (human), 610  
 Betaxolol,  $\beta_2$ -adrenergic receptor up-regulation by, in neuroblastoma x glioma hybrid cell (human), 1479  
 BIBP 3226, binding site of (human), 285  
 BIBW22 BS, multidrug resistance reversal by (human), 482  
 Bombesin-like peptide receptor  
   high affinity agonists of (mouse), 1355  
   mutagenesis and (mouse), 1346  
 Bone marrow, stromal adipogenesis in, thiazolidinedione induction of (mouse), 1087  
 Bone marrow progenitor cell, apoptosis of, benzene metabolite induction of (human), 610  
 Brain  
   cytochrome P4502D4 in, clozapine and toluene regulation of (rat), 342  
   melanocortin-4 receptor in, morphine regulation of (rat), 583  
   MPTP-lesioned, dopamine receptor mRNA in (monkey), 1073  
 Breast cancer cell, camptothecin resistance of (human), 1472  
 Butyrylcholinesterase, drug interaction sites of (human), 1423

## C

- Calcineurin, T lymphocyte cyclosporin A resistance and (human), 506  
 Calcium  
   calcium release induced by, 5-hydroxytryptamine receptor inhibition of, hippocampal after hyperpolarization and (rat), 1316  
   capacitative influx of, farnesylcysteine analog inhibition of (human), 1495  
   inositol trisphosphate regioisomers mobilization of (rabbit), 1223  
   kinin receptor mobilization of, in vascular smooth muscle cell (rabbit), 128  
   mobilization of, phosphoinositidase C-linked G protein<sup>+</sup> and (mouse), 493  
   potassium channel activated by, blockers and openers of (human, mouse), 206  
 Calcium channel  
   FTX-3.3 block of (rat), 939  
   metabotropic glutamate receptor inhibition of (human), 912  
   opioid receptor inhibition of (rat), 947  
   vasopressin stimulation of (rat), 1273  
 Calcium channel blocker  
   high affinity binding of, subunit composition and (COS cells), 1330  
   5-hydroxytryptamine receptor inhibition by (human), 1284  
   phenylalanine as (human), 1388  
 Calcium current, cardiac, forskolin inhibition of (guinea pig), 1262  
 Calcium pump isoforms, pharmacological differentiation between (rat), 1243  
 Camptothecin  
   breast cancer cell resistance to (human), 1472  
   cell sensitivity to, in p53-associated multidrug resistance (human), 1536  
 Carbacho, insulin release and (rat), 1047  
 Cardiomyopathy, protein kinase C potentiation of cAMP-dependent phosphodiesterase isozyme in (hamster), 549  
 Catecholaminergic cell, derived from central nervous system, dopamine-induced apoptosis of (mouse), 1309

- Cell killing, *see also* Apoptosis  
   by antitopoisomerase agents (yeast), 1095  
 Central nervous system, catecholaminergic cell death in, dopamine induction of (mouse), 1309  
 Cerebellar granule cell  
   apoptosis of, PACAP receptor and (rat), 60  
   GABA receptor pharmacology in, furosemide and (rat), 23  
 1-(*m*-Chlorophenyl)-biguanine, 5-hydroxytryptamine receptor activation by (human), 1284  
 Cholecystokinin B/gastrin receptor, gastrin affinity conferred by (*Xenopus*), 436  
 Cidofovir, cellular enzyme phosphorylation of, cytomegalovirus infection and (human), 1502  
 Ciprofloxacin, mitochondrial DNA cytotoxicity and cleavage delayed by (hamster, human, mouse), 1178  
 Cisplatin  
   cell sensitivity to, in p53-associated multidrug resistance (human), 1536  
   resistance to, in *Schizosaccharomyces pombe*, 1080  
 Clodronate, apoptosis induction by, in osteoclasts and macrophages (rat), 1127  
 Clozapine, brain cytochrome P4502D4 regulation by (rat), 342  
 Conotoxin, Ca<sup>2+</sup> channel sensitive to, metabotropic glutamate receptor inhibition of (human), 912  
 Corticotropin-releasing factor receptor  
   sauvagine as radiolabel for (human), 679  
   stress and agonist regulation of (rat), 1103  
 CP-339,818, voltage-gated K<sup>+</sup> channel blockade by (rat), 1672  
 CRF receptor, *see* Corticotropin-releasing factor receptor  
 CTOP, as nonopioid receptor agonist, in locus ceruleus neuron (rat), 650  
 Cyclic adenosine monophosphate  
   accumulation of, phospholipase A<sub>2</sub> and (hamster), 1017  
   phosphodiesterase isozyme dependent on, protein kinase C potentiation of, in cardiomyopathy (hamster), 549  
 Cyclic guanosine monophosphate, nitroprusside-induced, thrombin-stimulated phospholipase C activity and (human), 367  
 Cyclosporin A, T lymphocyte resistance to, calcineurin mutants and (human), 506  
*CYP1A1* and *CYP1A2*, piperonyl butoxide and acenaphthylene induction of, in hepatic aromatic hydrocarbon-responsive receptor (mouse), 443  
*CYP2A3* and *CYP2A6*, baculovirus-mediated expression of, olfactory toxicity and (rat, human), 781  
*CYP2A8* gene, methylcholanthrene-induced, okadaic acid and (hamster), 556  
*CYP2C9* gene, epitope mapping of, in autoimmune hepatitis (human, rabbit), 326  
*CYP2E1* protein  
   as cell surface autoantigen, in halothane hepatitis (rat), 573  
   induction of, by inflammatory factors and ischemic injury, in astrocytes (gerbil, rat), 1065  
*CYP2J* family, in lung (human, rat), 1111  
*CYP3A* gene  
   polymorphic renal (human), 52  
   trans-species transfer of, in hepatocyte (human, rabbit, rat), 10  
*CYP3A1* gene, metyrapone induction of, glucocorticoid and (rat), 856  
 Cytochrome P450, *see also* *CYP* entries  
   heme in transcription and function of, lead effects on (mouse), 474  
   hepatic, GH feminization of (rat), 1148  
 Cytochrome P4502D4, in brain, clozapine and toluene regulation of (rat), 342  
 Cytokine, macrophage PMEPA antiviral activity and (human), 359  
 Cytomegalovirus infection, cidofovir phosphorylation and (human), 1502

## D

## DAMGO

- binding of,  $\delta$ -opioid receptor lysine prevention of (rat), 1413
- $\mu$ -opioid receptor functional desensitization by (hamster), 1214
- DE-diaphorase, quinone toxicity and (hamster, human), 728
- Dehydroepiandrosterone sulfate, PPAR activation by (rabbit), 67
- Dentate granule cell, GABA receptor in (rat), 458
- Deoxyribonucleic acid
  - anthracenedione binding to, sequence specificity of (human), 838
  - AP-1 binding of, penicillamine and (human), 501
  - mitochondrial, ciprofloxacin delay of cytotoxicity and cleavage in (hamster, human, mouse), 1178
  - PDGF-induced synthesis of, tranilast blockade of, in vascular smooth muscle cell (rat), 763
  - repair of, in breast cancer cell, camptothecin resistance and (human), 1472
- DHEA-S, *see* Dehydroepiandrosterone sulfate
- Diabetic nephropathy, vasopressin receptor mutation and (human), 820
- Diazepam, GABA receptor insensitive to, pharmacological modulation of (human), 1253
- Dicaffeoylquinic acid, HIV integrase inhibition by (human), 846
- Didehydro-3'-deoxythymidine, *see* Stavudine (Zerit)
- Dideoxycytidine, transport of (*Xenopus*), 388
- Dihydropyridine, binding site for, in glomerulosa cell, vasopressin receptor coupling to (rat), 1273
- Dihydroxyphenylalanine, to reverse effects of MPTP-lesioned brain, dopamine receptor mRNA and (monkey), 1073
- Diltiazem, 5-hydroxytryptamine receptor inhibition by (human), 1284
- Dofetilide, inward rectifier K<sup>+</sup> channel blockade by (human), 380
- Dopamine, catecholaminergic central nervous system cell apoptosis induction by (mouse), 1309
- Dopamine receptor
  - adenylate cyclase sensitization by (human), 966
  - amiloride regulation of (rat), 1295
  - effect on, of mutagenesis of residues adjacent to transmembrane prolines (human), 1338
  - L-750,667 as radioligand for (human), 1658
  - in MPTP-lesioned brain (monkey), 1073
- Dorsal horn, neurokinin-1 receptor in, LY306,740 blockade of nociception-induced increases in (rat), 1189
- Drug interaction sites, of butyrylcholinesterase (human), 1423
- Drug resistance, of *Plasmodium falciparum*, 1551, 1559
- Drug screening, glutathione-associated enzymes in (human), 149
- Drug sensitivity, of DNA topoisomerase II (human), 1463
- D4T, *see* Stavudine (Zerit)
- Dynorphin selectivity, orphanin FQ and (*Xenopus*), 447

## E

- EGF receptor, *see* Epidermal growth factor receptor
- Endothelial cell, coronary, acetylcholine-induced prostacyclin synthesis in (rabbit), 1139
- Enkephalin DAMGO
  - binding of,  $\delta$ -opioid receptor lysine prevention of (rat), 1413
  - $\mu$ -opioid receptor functional desensitization by (hamster), 1214
- Enzyme, cellular, cidofovir phosphorylation by, cytomegalovirus infection and (human), 1502
- Epidermal growth factor receptor, phosphorothioate oligodeoxynucleotide directed against (A431 cell), 314
- Epithelial cell, renal
  - adrenoceptor-activated phospholipase C in (mouse), 407
  - gadd153* gene expression in, quinone thioether and (minipig), 592
- Erythroleukemia cell, differentiation of, PMEA and (human), 1231
- Ethanol
  - action of, on strychnine-sensitive glycine receptor (*Xenopus*), 402

- nicotinic acetylcholine receptor inhibition by (*Xenopus*), 1010
- Etoposide resistance, topoisomerase II phosphorylation and, in leukemia cell (human), 243
- Evans blue, as AMPA and kainate receptor antagonist (human), 1665

## F

- Farnesylcysteine analog, capacitative Ca<sup>2+</sup> influx and (human), 1495
- Feminization, of hepatic cytochrome P450 by GH (rat), 1148
- Fluoroanthracycline, biochemistry and pharmacology of (human), 603
- Forskolin
  - aldosterone synthesis evoked by, guanylyl cyclase A-selective agonist inhibition of (human), 430
  - isothiocyanate derivative of, adenylyl cyclase and (SF9 cell), 299
- FSCPX, as irreversible antagonist of  $\alpha_1$ -adrenoceptor, 196
- FTX-3.3, calcium channel block by (rat), 939
- Furosemide, cerebellar GABA receptor pharmacology and (rat), 23

## G

- G protein
  - activation of, and ICI-174,864 effect on  $\delta$ -opioid receptor (human), 1651
  - adenosine receptors and (bovine), 1587
  - carboxyl-terminal mutations of, receptor activation and (hamster, human), 885
  - metabotropic glutamate receptor coupling to (human), 923
  - muscarinic K<sup>+</sup> channel regulated by, volatile anesthetics and (bullfrog), 1520
  - opioid analgesia and (mouse), 293
  - $\delta$ -opioid receptor interaction with, sites of (mouse), 985
  - PGE receptor subtypes coupled to, differential properties of (hamster), 1031
  - phosphoinositidase C-linked, Ca<sup>2+</sup> mobilization and (mouse), 493
  - phospholipase C potentiation by (human), 1038
  - purinoceptor coupled to, nucleoside diphosphate activation of (chicken), 258
  - receptor coupling to, suramin analog inhibition of (human), 415
  - VIP receptor coupling to, in lung (rat), 624
- G protein-coupled receptor, inositol phosphate formation by, toxin B inhibition of, in neuroblastoma cell (N1E-115 cells), 864
- GABA receptor, *see*  $\gamma$ -Aminobutyric acid receptor
- gadd153* gene, quinone thioether and, in renal epithelial cell (minipig), 592
- Gastrin affinity, cholecystokinin B/gastrin receptor domains and (*Xenopus*), 436
- Gastrin-releasing peptide receptor, phosphorylation of (hamster, mouse), 716
- Genistein, inhibitor of TPA-induced ornithine decarboxylase activity by (monkey), 249
- GH, *see* Growth hormone
- Glioblastoma, antisense protein kinase C for (mouse), 236
- Glioma cell,  $\beta_1$ - and  $\beta_2$ -adrenoceptors in (rat), 175
- Glioma x neuroblastoma hybrid cell, agonist-induced  $\beta_2$ -adrenergic receptor up-regulation in (human), 1479
- Glomerulosa cell, dihydropyridine binding sites in, vasopressin receptor coupling to (rat), 1273
- Glucocorticoid, and metyrapone induction of *CYP3A1* gene (rat), 856
- Glutamate receptor, metabotropic
  - Ca<sup>2+</sup> channel inhibition by (human), 912
  - G protein coupling to (human), 923
  - PCCG as antagonist of (hamster), 6
- Glutathione-associated enzyme, in NCI drug screening (human), 149
- Glycine, NDMA receptor activation by (mouse), 701

Glycine receptor, strychnine-sensitive, ethanol action on (*Xenopus*), 402  
 Glycine receptor antagonists, from quinolinic acid compounds (*Xenopus*), 1200  
 Glycoprotein, *see also* P-glycoprotein  
 Granule cell  
   cerebellar, *see* Cerebellar granule cell  
   dentate, GABA receptor in (rat), 458  
 Growth hormone, hepatic cytochrome P450 feminization by (rat), 1148  
 Guanosine monophosphate, cyclic, *see* Cyclic guanosine monophosphate  
 Guanylyl cyclase, ODQ inhibition of (bovine), 1  
 Guanylyl cyclase A-selective agonist, aldosterone synthesis and (human), 430

## H

Haloperidol, NDMA inhibition by (rat, *Xenopus*), 1541  
 Halothane hepatitis, CYP2E1 as cell surface autoantigen in (rat), 573  
 Heart  
   calcium current in, forskolin inhibition of (guinea pig), 1262  
   endothelial cells of, acetylcholine-induced prostacyclin synthesis in (rabbit), 1139  
 Helix 5 locus, selectivity of, 5-hydroxytryptamine receptor and (human), 34  
 Heme, in cytochrome P450 transcription and function, lead effects on (mouse), 474  
 Hepatitis  
   autoimmune, CYP2C9 gene epitope mapping in (human, rabbit), 326  
   halothane, CYP2E1 as cell surface autoantigen in (rat), 573  
 Hepatocyte  
   trans-species CYP3A gene transfer in (human, rabbit, rat), 10  
   vitamin C in, antioxidant function of (rat), 994  
 Hepatoma, loss of aryl hydrocarbon receptor gene in (mouse), 1454  
 Herpes simplex virus, macrophage PMEA inhibition of (human), 359  
 Hippocampus, after hyperpolarization in, 5-hydroxytryptamine receptor reduction of (rat), 1316  
 HIV, *see* Human immunodeficiency virus  
 Human immunodeficiency virus  
   antiestrogen effect on (human), 75  
   macrophage PMEA inhibition of (human), 359  
   reverse transcriptase of, TSAO and nevirapine inhibition of (human), 1057  
   thiocarboxanilide ether derivative inhibitor of (human), 394  
 Human immunodeficiency virus integrase, dicafeoylquinic acid inhibition of (human), 846  
 $\alpha$ -Hydroxyethyl free radical adduct, pancreatic, chronic alcohol exposure and (rat), 656  
 17 $\beta$ -Hydroxysteroid dehydrogenase, as peroxisome proliferator chemical (rat), 1157  
 5-Hydroxytryptamine receptor  
   activation of, arachidonic acid metabolism and (hamster), 1017  
   alniditan binding by (bovine, human), 1567  
   Ca<sup>2+</sup> channel antagonist inhibition of (human), 1284  
   Ca<sup>2+</sup>-induced calcium release inhibition by, hippocampal after hyperpolarization and (rat), 1316  
   helix 5 locus selectivity and (human), 34  
   rapid agonist-induced internalization of (rat), 306  
   spliced variant of (human, mouse, rat), 799  
   in target tissues for antimigraine drugs (human), 219  
 5-Hydroxytryptamine-moduline, serotonergic regulation by (guinea pig, rat), 752  
 Hypothalamus, synaptic transmission in, leptin and (rat), 230

## I

ICI-174,864, effect of, on  $\delta$ -opioid receptor (human), 1651  
 Inflammatory factors, CYP2E1 protein induction by, in astrocytes (gerbil, rat), 1065  
 Inositol phosphate, toxin B inhibition of, in neuroblastoma cell (N1E-115 cells), 864  
 Inositol trisphosphate regioisomers, Ca<sup>2+</sup> mobilization by (rabbit), 1223  
 Insulin release, PACAP and (rat), 1047  
 Integrin  $\alpha/\beta_3$  receptor, ligand interaction with (human), 529  
 Ischemic injury, CYP2E1 protein induction by, in astrocytes (gerbil, rat), 1065  
 Isothiocyanate derivative of forskolin, adenylyl cyclase and (Sf9 cell), 299

## K

Kainate receptor  
   characterization and mutational analysis of (goldfish), 770  
   Evans blue as antagonist for (human), 1665  
 Kidney  
   CYP3A gene polymorphism in (human), 52  
   epithelial cell in  
     adrenoceptor-activated phospholipase C in (mouse), 407  
     gadd153 gene expression in, quinone thioether and (minipig), 592  
 KINFIT II, to analyze kinetic binding data, 86  
 Kinin receptor, Ca<sup>2+</sup> mobilization by, in vascular smooth muscle cells (rabbit), 128

## L

L-750,667, as dopamine receptor radioligand (human), 1658  
 Lead, effect on heme role in cytochrome P450 transcription and function (mouse), 474  
 Leptin, synaptic transmission and, in hypothalamus (rat), 230  
 Leukemia, etoposide resistance in, topoisomerase II phosphorylation and (human), 243  
 Lipopolysaccharide, nitric oxide synthase induced by, tetrahydrocannabinol inhibition of (mouse), 334  
 Liver  
   aromatic hydrocarbon-responsive receptor in, piperonyl butoxide and acenaphthylene induction of CYP1A1 and CYP1A2 in (mouse), 443  
   cytochrome P450 in, GH feminization of (rat), 1148  
   male-dominant sulfotransferases in (rat), 565  
   nitric oxide synthase in, 277  
 Locus ceruleus neuron, CTOP as nonopioid receptor agonist in (rat), 650  
 LPS, *see* Lipopolysaccharide  
 Lung  
   coupling of VIP receptor to G protein in (rat), 624  
   CYP2J family in (human, rat), 1111  
 LY306,740, blockade of nociception-induced increases in dorsal horn neurokinin-1 receptor by (rat), 1189  
 Lysophosphatidic acid receptor, antagonists of (*Xenopus*), 616

## M

Macrophage  
   acemannan-induced production of nitric acid in (mouse), 878  
   clodronate-induced apoptosis in (rat), 1127  
   PMEA in, antiviral activity of (human), 359  
 MAP kinase, *see* Mitogen-activated protein kinase  
 Melanocortin-4 receptor, morphine regulation of (rat), 583  
 Melatonin receptor, regulation of (hamster, human), 166  
 Mercury binding site, on Na<sup>+</sup>/K<sup>+</sup>-ATPase (*Xenopus*), 687  
 Metabotropic glutamate receptor

- Ca<sup>2+</sup> channel inhibition by (human), 912  
 G protein coupling to (human), 923  
 PCCG as antagonist of (hamster), 6  
 Methylcholanthrene, *CYP2A8* gene induced by, okadaic acid and (hamster), 556  
*N*-Methyl-D-aspartate receptor  
   developmental changes in (rat), 631  
   glycine activation of (mouse), 701  
   haloperidol inhibition of (rat, *Xenopus*), 1541  
 1-Methyl-4-phenyl-1,2,3,6-tetrahydropine  
   brains lesioned with, dopamine receptor mRNA in (monkey), 1073  
   neurotoxicity of, superoxide dismutase and (mouse), 1511  
 Metyrapone, *CYP3A1* induction by, glucocorticoid and (rat), 856  
 Migraine, drugs for, 5-hydroxytryptamine receptors in target tissues for (human), 219  
 Mitochondrial DNA, ciprofloxacin delay of cytotoxicity and cleavage in (hamster, human, mouse), 1178  
 Mitogen-activated protein kinase  
   in acetylcholine-induced prostacyclin synthesis, in coronary endothelial cells (rabbit), 1139  
    $\mu$ -opioid receptor and (hamster), 599  
 Mitoxantrone, nitrous acid oxidation of, 1612  
 Morphine, melanocortin-4 receptor regulation by (rat), 583  
 Mossy fiber, neurotransmitter release from,  $\kappa$ -opioid receptor-activated potassium channel and (guinea pig), 80  
 MPTP, *see* 1-Methyl-4-phenyl-1,2,3,6-tetrahydropine  
 Multidrug resistance  
   BIBW22 BS reversal of (human), 482  
   p53-associated, cell sensitivity to cisplatin, camptothecin, and taxol in (human), 1536  
   P-glycoprotein associated with, phosphorothioate inhibition of (mouse), 808  
 Muscarinic acetylcholine receptor  
   arginine/lysine in (hamster), 140  
   internalization and resensitization of (mouse), 424  
   phospholipase C potentiation by (human), 1038  
 Muscarinic potassium channel, G protein-regulated, volatile anesthetics and (bullfrog), 1520

## N

- NAD(P)H:quinone oxidoreductase, quinone toxicity and (hamster, human), 728  
 Na<sup>+</sup>/K<sup>+</sup>-ATPase, mercury binding site on (*Xenopus*), 687  
 Nephropathy, diabetic, vasopressin receptor mutation and (human), 820  
 Neuroblastoma cell, inositol phosphate formation in, toxin B inhibition of (N1E-115 cell), 864  
 Neuroblastoma x glioma hybrid cell, agonist-induced  $\beta_2$ -adrenergic receptor up-regulation in (human), 1479  
 Neurokinin-1 receptor  
   antagonist binding to, polar interactions and conformational compatibility in (human), 1605  
   in dorsal horn, LY306,740 blockade of nociception-induced increases in (rat), 1189  
 Neuron, apoptosis of, PACAP receptor and (rat), 60  
 Neuropeptide Y receptor antagonist, binding site of (human), 285  
 Neurotransmitter release, from mossy fiber,  $\kappa$ -opioid receptor-activated potassium channel and (guinea pig), 80  
 Nevirapine, HIV reverse transcriptase inhibition by (human), 1057  
 NF- $\kappa$ B, *see* Nuclear factor- $\kappa$ B  
 Nicotinic acetylcholine receptor  
   agonist binding site of, unnatural amino acids at (*Xenopus*), 1401  
   ethanol inhibition of (*Xenopus*), 1010  
 Nimodipine, 5-hydroxytryptamine receptor inhibition by (human), 1284  
 Nitric oxide  
   acemannan-induced production of, in macrophage (mouse), 878

- guanylyl cyclase sensitive to, ODQ inhibition of (bovine), 1  
 Nitric oxide synthase  
   hepatic (human), 277  
   LPS-induced, tetrahydrocannabinol inhibition of (mouse), 334  
 Nitroprusside, cGMP induced by, thrombin-stimulated phospholipase C activity and (human), 367  
 Nitrous acid, mitoxantrone oxidation by, 1612  
 NMDA, *see* *N*-Methyl-D-aspartate receptor  
 Nociception, dorsal horn neurokinin-1 receptor increases induced by, LY306,740 blockade of (rat), 1189  
 Norepinephrine transporter, glycosylation and (human), 266  
 Nuclear factor- $\kappa$ B/Rel, tetrahydrocannabinol inhibition of (mouse), 334  
 Nucleoside diphosphate, G protein-coupled purinoceptor activation by (chicken), 258

## O

- ODQ, *see* 1*H*-[1,2,4,]Oxadiazolo[4,3- $\alpha$ ]quinoxalin-1-one  
 Okadaic acid, methylcholanthrene-induced *CYP2A8* gene expression and (hamster), 556  
 Olfactory toxicity, baculovirus-mediated *CYP2A3* and *CYP2A6* expression and (rat, human), 781  
 Oligonucleotide, glycosylated poly-L-lysine complexed with (human), 1487  
 Opiate addiction, melanocortin-4 receptor in, morphine regulation of (rat), 583  
 Opioid analgesia, G proteins and (mouse), 293  
 Opioid receptor(s)  
   Ca<sup>2+</sup> channel inhibition by (rat), 947  
   phospholipase C activation and adenylyl cyclase inhibition mediated by, in smooth muscle (guinea pig), 870  
 $\delta$ -Opioid receptor  
   agonist selectivity and (human), 1619  
   effect of ICI-174,864 on (human), 1651  
   enkephalin DAMGO binding prevention by (rat), 1413  
   G protein interaction with, sites of (mouse), 985  
 $\kappa$ -Opioid receptor  
   coupling of, to potassium channel (guinea pig), 80  
   mutation of, agonist affinity and (rat), 977  
 $\mu$ -Opioid receptor  
   adenylyl cyclase isoforms and (mouse), 43  
   agonist-induced functional desensitization of (hamster), 1214  
   MAP kinase activity and (hamster), 599  
 Ornithine decarboxylase, TPA induction of, genistein inhibition of (monkey), 249  
 Orphanin FQ, dynorphin selectivity and (*Xenopus*), 447  
 Osteoclast, clodronate-induced apoptosis in (rat), 1127  
 Ovary,  $\alpha_1$ -adrenoceptor of, PD81,723 effects on (hamster, human), 104  
 1*H*-[1,2,4,]Oxadiazolo[4,3- $\alpha$ ]quinoxalin-1-one, guanylyl cyclase inhibition by (bovine), 1  
 Oxime reactivator, interaction of phosphorylated acetylcholinesterase mutants with (human), 639

## P

- p53  
   multidrug resistance-associated, and cell sensitivity to cisplatin, camptothecin, and taxol (human), 1536  
   T lymphocyte apoptosis and (rat), 900  
 PACAP receptor, *see* Pituitary adenylate cyclase-activating polypeptide receptor  
 Palmitoylserine phosphoric acid, as antagonist of lysophosphatidic acid receptor (*Xenopus*), 616  
 Palmitoyltyrosine phosphoric acid, as antagonist of lysophosphatidic acid receptor (*Xenopus*), 616

- Pancreas,  $\alpha$ -hydroxyethyl free radical adducts in, chronic alcohol exposure and (rat), 656
- Pancreatic polypeptide receptor, structure-activity of (human), 112
- PCCG, *see* Phenylcyclopropylglycine
- PD81,723,  $\alpha_1$ -adrenoceptor effects of (hamster, human), 104
- PDGF, *see* Platelet-derived growth factor
- Penicillamine, AP-1 DNA binding and (human), 501
- Peroxisome proliferator chemical, 17 $\beta$ -hydroxysteroid dehydrogenase as (rat), 1157
- Peroxisome proliferator-activated receptor  
DHEA-S activation of (rabbit), 67  
thiazolidinedione-activated, induction of bone marrow stromal cell adipogenesis by (mouse), 1087
- PGE, *see* Prostaglandin E
- P-glycoprotein, multidrug resistance-associated, phosphorothioate inhibition of (mouse), 808
- Phenylalanine  
as calcium channel blocker (human), 1388  
in serotonin transporter interaction with tricyclic antidepressant (human), 957
- Phenylalkylamine, voltage-gated K<sup>+</sup> channel and (mouse), 1625
- Phenylcyclopropylglycine, as antagonist of metabotropic glutamate receptor (hamster), 6
- Pheromone response pathway, of yeast, adenosine receptor coupled to, pharmacologic characterization of (rat), 829
- Phorbol myristate acetate,  $\alpha_1$ -adrenoceptor subtypes and (rat), 17
- Phosphodiesterase 4A, catalytic activity and rolipram binding by (human), 891
- Phosphodiesterase isozyme, protein kinase C potentiation of, in cardiomyopathy (hamster), 549
- Phosphoinositidase C, G protein linked to, Ca<sup>2+</sup> mobilization and (mouse), 493
- Phospholipase A<sub>2</sub>  
in acetylcholine-induced prostacyclin synthesis, in coronary endothelial cells (rabbit), 1139  
cAMP accumulation and (hamster), 1017
- Phospholipase C  
adrenoceptor-activated, in renal epithelial cell (mouse), 407  
muscarinic receptor-induced potentiation of (human), 1038  
thrombin-stimulated, nitroprusside-induced cGMP level and (human), 367
- Phospholipase C- $\beta$ 3, opioid receptor-mediated activation of, in smooth muscle (guinea pig), 870
- 9-(2-Phosphonylmethoxyethyl)adenine  
antiviral activity of (human), 359  
erythroleukemia cell differentiation and (human), 1231
- Phosphorothioate, inhibition of multidrug resistance-associated P-glycoprotein with (mouse), 808
- Phosphorothioate oligodeoxynucleotide  
directed against EGF receptor (A431 cell), 314  
for glioblastoma (mouse), 236
- Piperonyl butoxide, CYP1A1 and CYP1A2 induction by, in hepatic aromatic hydrocarbon-responsive receptor (mouse), 443
- Pituitary adenylate cyclase-activating polypeptide  
insulin release and (rat), 1047  
multiple receptor states of (hamster), 1596
- Pituitary adenylate cyclase-activating polypeptide receptor, neuronal apoptosis and (rat), 60
- Plasmodium falciparum*  
4-aminoquinoline resistance of, 1551  
drug resistance of, reversal of, 1559
- Platelet-derived growth factor, DNA synthesis induced by, tranilast blockade of, in vascular smooth muscle cell (rat), 763
- PMA, *see* Phorbol myristate acetate
- PMEA, *see* 9-(2-Phosphonylmethoxyethyl)adenine
- Poly-L-lysine, glycosylated, oligonucleotide complexed with (human), 1487
- Potassium channel  
Ca<sup>2+</sup>-activated, blockers and openers of (human, mouse), 206  
CTOP as nonopioid receptor agonist in (rat), 650  
G protein-regulated muscarinic, volatile anesthetics and (bull-frog), 1520  
inward rectifier, dofetilide blockade of (human), 380  
 $\kappa$ -opioid receptor coupling to (guinea pig), 80  
orphanin FQ and (*Xenopus*), 447  
voltage-gated  
nonpeptide blockade of (rat), 1672  
phenylalkylamine and (mouse), 1625  
scorpion toxin blockade of, 1167
- PPAR, *see* Peroxisome proliferator-activated receptor
- Proline, transmembrane, mutagenesis of residues adjacent to, dopamine receptor effects of (human), 1338
- Prostacyclin, acetylcholine-induced synthesis of, in coronary endothelial cells (rabbit), 1139
- Prostaglandin E receptor, G protein-coupled subtypes of, differential properties of (hamster), 1031
- Prostaglandin transporter, substrates for (human), 736
- Protein kinase C  
angiotensin II receptor signaling and (hamster), 522  
GABA receptor function and (bovine), 185  
gastrin-releasing peptide receptor phosphorylation and (hamster, mouse), 716  
for glioblastoma (mouse), 236  
potentiation of cAMP-dependent phosphodiesterase isozyme by, in cardiomyopathy (hamster), 549
- Purinoceptor, G protein-coupled, nucleoside diphosphate activation of (chicken), 258
- P2Y<sub>1</sub> receptor, competitive antagonists of (human, rat, turkey), 1323
- ## Q
- Quinolinic acid compounds, glycine receptor antagonists derived from (*Xenopus*), 1200
- Quinone, toxicity of, NQO1 and (hamster, human), 728
- Quinone thioether, *gadd153* expression and, in renal epithelial cell (minipig), 592
- ## R
- Raf-1, angiotensin II receptor signaling through (hamster), 522
- Rolipram, phosphodiesterase 4A binding of (human), 891
- Ryanodine receptor, on skeletal muscle, suramin activation of (rabbit), 1443
- ## S
- Sauvagine, as CRF receptor radiolabel (human), 679
- Schizosaccharomyces pombe*, cisplatin-resistant, 1080
- Scorpion toxin, voltage-gated K<sup>+</sup> channel blockade by, 1167
- Serotonergic regulation, by 5-hydroxytryptamine-moduline (guinea pig, rat), 752
- Serotonin transporter, tricyclic antidepressant interaction with, phenylalanine 586 in (human), 957
- Skeletal muscle, ryanodine receptor of, suramin activation of (rabbit), 1443
- Smooth muscle, opioid receptor-mediated phospholipase C activation and adenylyl cyclase inhibition in (guinea pig), 870
- Smooth muscle cell, vascular, *see* Vascular smooth muscle cell
- So324, antiretroviral specificity and intracellular metabolism of (cat), 1207
- Sodium, adenosine transport dependent on (rat, *Xenopus*), 1529
- Sodium channel, inactivation-deficient, block of (frog), 1643
- Somatostatin antagonist, identification and characterization of (rat), 709
- Sphingosine 1-phosphate, AP-1 activation and (rat), 451
- Sphingosynphosphocholine, AP-1 activation and (rat), 451

- Stavudine (Zerit)  
 antiretroviral specificity and intracellular metabolism of (cat), 1207  
 phosphorylation of, regulation of (human), 160  
 Steroid enantiomers, GABA<sub>A</sub> receptors and (rat), 1581  
 Stress, CRF receptor regulation by (rat), 1103  
 Stromal cell, of bone marrow, adipogenesis in, thiazolidinedione induction of (mouse), 1087  
 Strychnine, glycine receptor sensitive to, ethanol action on (*Xenopus*), 402  
 Sulfotransferase, male-dominant, in liver (rat), 565  
 Sumatriptan, target tissues for, 5-hydroxytryptamine receptors in (human), 219  
 Superoxide dismutase, MPTP analog neurotoxicity and (mouse), 1511  
 Suramin, ryanodine receptor activation by, on skeletal muscle (rabbit), 1443  
 Suramin analog, receptor/G protein coupling inhibition by (human), 415  
 Synaptic transmission, in hypothalamus, leptin and (rat), 230
- T**
- T lymphocyte  
 apoptosis of, p53 and (rat), 900  
 cyclosporin A resistance of, calcineurin mutants and (human), 506  
 Tamoxifen, anti-HIV effects of (human), 75  
 Taxol, cell sensitivity to, in p53-associated multidrug resistance (human), 1536  
 12-*O*-Tetradecanoylphorbol-13-acetate, ornithine decarboxylase activity induced by, genistein inhibition of (monkey), 249  
 Tetrahydrocannabinol  
 inhibition of LPS-induced nitric oxide synthase by (mouse), 334  
 inhibition of NF- $\kappa$ B/Rel binding by (mouse), 334  
 Thiazolidinedione, induction of bone marrow stromal cell adipogenesis by (mouse), 1087  
 Thiocarboxanilide pentenyl ether derivative, HIV inhibition by (human), 394  
 Thrombin, phospholipase C stimulated by, nitroprusside-induced cGMP level and (human), 367  
 Thymidine triphosphate, biosynthesis of, stavudine phosphorylation and (human), 160  
 Toluene, brain cytochrome P4502D4 regulation by (rat), 342  
 Topoisomerase, cell killing by (yeast), 1095  
 Topoisomerase I, in breast cancer cell, camptothecin resistance and (human), 1472  
 Topoisomerase II  
 drug sensitivity and sequence specificity of (human), 1463  
 phosphorylation of, etoposide resistance and, in leukemia cell (human), 243  
 Toxin B, inhibition of inositol phosphate formation by, in neuroblastoma cell (N1E-115 cells), 864  
 TPA, *see* 12-*O*-Tetradecanoylphorbol-13-acetate  
 Tranilast, PDGF-induced DNA synthesis blockade by, in vascular smooth muscle cell (rat), 763  
 Tricyclic antidepressant, serotonin transporter interaction with, phenylalanine 586 in (human), 957  
 TSAO, HIV reverse transcriptase inhibition by (human), 1057  
 Tyrosine kinase receptor, inositol phosphate formation by, toxin B inhibition of, in neuroblastoma cell (N1E-115 cells), 864
- U**
- UC-781, HIV inhibition by (human), 394  
 Uridine nucleotide receptors, in astrocytoma cells (human), 224
- V**
- Vascular smooth muscle cell  
 angiotensin receptor mRNA-binding protein in (rat), 743  
 ATP-induced proliferation of (rat), 1000  
 kinin receptor mobilization of Ca<sup>2+</sup> in (rabbit), 128  
 tranilast blockade of PDGF-induced DNA synthesis in (rat), 763  
 Vasoactive intestinal peptide, multiple receptor states of (hamster), 1596  
 Vasoactive intestinal peptide receptor, G protein coupling to, in lung (rat), 624  
 Vasopressin, calcium channel stimulation by (rat), 1273  
 Vasopressin receptor  
 diabetic nephrogenic mutants of (human), 820  
 nonglycosylated (human), 467  
 Verapamil, 5-hydroxytryptamine receptor inhibition by (human), 1284  
 VIP receptor, *see* Vasoactive intestinal peptide receptor  
 Vitamin C, antioxidant function of (rat), 994  
 Vitronectin receptor, ligand interaction with (human), 529  
 Volatile anesthetics, effects of, on G protein-regulated muscarinic K<sup>+</sup> channel (bullfrog), 1520
- Z**
- Zerit, *see* Stavudine (Zerit)  
 Zona glomerulosa cell, aldosterone synthesis in, guanylyl cyclase A-selective agonist inhibition of (human), 430

**STATEMENT OF OWNERSHIP MANAGEMENT AND CIRCULATION (Required by 39 U.S.C. 3685)**

1. Publication Title: MOLECULAR PHARMACOLOGY; 2. Publication no.: 0026-895X.
3. Filing Date: 10-01-96. 4. Frequency of issue: Monthly; 5. No. of issues published annually: 12; 6. Annual subscription price: \$115.00. 7. Complete mailing address of known office of publication: 351 West Camden Street, Baltimore, MD 21201-2436.
8. Complete mailing address of the headquarters of general business offices of the publisher: 351 West Camden Street, Baltimore, MD 21201-2436.
9. Full names and complete mailing address of publisher, editor, and managing editor: Publisher: Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201-2436; Editor: Raymond J. Dingledine, Ph.D., Emory University School of Medicine, 5001 Rollins Research Center, Clifton Road, Atlanta, GA 30322-3090. Managing Editor: Esmeralda Galán, Emory University School of Medicine, 5001 Rollins Research Center, Clifton Road, Atlanta, GA 30322-3090. 10. Owner: American Society of Pharmacology and Experimental Therapeutics, c/o Kay Croker, Executive Director, 9650 Rockville Pike, Bethesda, MD 20814.
11. Known bondholders, mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities: None.
12. Purpose, function, and nonprofit status: Has not changed during preceding 12 months.
13. Publication Name: MOLECULAR PHARMACOLOGY
14. Issue Date for circulation data: August, 1996, Vol. 50, #2.
15. Extent and nature of circulation: Average number of copies each issue during preceding 12 months: (a) Total No. copies (Net Press Run), 1989. (b) Paid and/or requested circulation; (1) Sales through dealers and carriers, street vendors and counter sales (not mailed), 178; (2) Paid or Requested mail subscriptions (include Advertisers Proof Copies/Exchange Copies), 1317. (c) Total paid and/or requested circulation (sum of 15b(1) and 15b(2)), 1495. (d) Free distribution by mail (samples, complimentary, and other free copies), 87. (e) Free distribution outside the mail (carriers or other means), none. (f) Total free distribution (sum of 15d and 15e), 87. (g) Total distribution (Sum of 15c and 15f) 1582. (h) Copies not distributed: (1) Office use, leftovers, spoiled, 407; (2) Return from news agents, none. (i) Total (sum of 15g, 15h(1), and 15h(2)), 1989. Percent Paid and/or Requested Circulation (15c/15g x 100) 94.50%. Actual no. copies of single issue published nearest to filing date: (a) Total no. copies (Net Press Run), 2038. (b) Paid and/or requested circulation; (1) Sales through dealers and carriers, street vendors and counter sales (not mailed), 210; (2) Paid or Requested mail subscriptions (include Advertisers Proof Copies/Exchange Copies), 1274. (c) Total paid and/or requested circulation (sum of 15b(1) and 15b(2)), 1484. (d) Free distribution by mail (samples, complimentary, and other free copies), 83. (e) Free distribution outside the mail (carriers or other means), none. (f) Total free distribution (sum of 15d and 15e), 83. (g) Total distribution (Sum of 15c and 15f), 1567. (h) Copies not distributed: (1) Office use, leftovers, spoiled, 471; (2) Return from news agents, none. (i) Total (sum of 15g, 15h(1), and 15h(2)), 2038. Percent Paid and/or Requested Circulation (15c/15g x 100), 94.70%.
16. This Statement of Ownership will be printed in the December issue of this publication.
17. I certify that the statements made by me above are correct and complete.

Alma J. Willis  
Publisher

**Copyright © 1996 by the American Society for  
Pharmacology and Experimental Therapeutics**

## Previous Editors

- 1965** Avram Goldstein, *Editor*. Stanford University.
- 1968** Paul Talalay, *Editor*; Donald S. Coffey, *Associate Editor*. Johns Hopkins University.
- 1971** Steven E. Mayer, *Editor*; Palmer W. Taylor, *Associate Editor*. University of California at San Diego.
- 1975** George I. Drummond, *Editor*; H. Joseph Goren, *Associate Editor*. University of Calgary.
- 1978** Norman Kirschner, *Editor*; Theodore A. Slotkin, *Associate Editor*. Duke University.
- 1983** Joel G. Hardman, *Editor*; Lee Limbird, F. Peter Guengerich, *Associate Editors*. Vanderbilt University.
- 1986** William A. Catterall, *Editor*; Joseph A. Beavo, Mont R. Juchau, Neil M. Nathanson, Daniel R. Storm, Frank F. Vincenzi, *Associate Editors*. University of Washington, Seattle.
- 1990** T. Kendall Harden, *Editor*; Raymond J. Dingleline, R. L. Juliano, James W. Putney, Jr., Kenneth D. Tew, Ronald G. Thurman, *Associate Editors*. University of North Carolina at Chapel Hill.



## Williams & Wilkins Quick Copies. Tell us today. Read it tomorrow.

**Y**ou can get copies of any article published in any Williams & Wilkins journal. It's fast – because we're the primary source, we can fax an article to you within **24 hours** of when we receive your request. It costs less – there are **no copyright fees** and the **cost of faxing is included in the price**. It's affordable – look at the table to the right.

### RATES, PER ARTICLE

|       |       |      |
|-------|-------|------|
| 1–5   | pages | \$12 |
| 6–10  | pages | \$15 |
| 11–15 | pages | \$18 |
| 16–20 | pages | \$21 |
| 21–25 | pages | \$24 |
| 26+   | pages | \$30 |

Additional charges  
for overnight delivery

*Fax, phone, or mail your order to:*

**Williams & Wilkins**

**Quick Copies**

351 W. Camden Street

Baltimore, MD 21201-2436

Call 1-800-354-9685 (toll free)

Fax 1-410-528-4458



**Williams & Wilkins**


A WAVERLY COMPANY

DDSAD 56189

# PHARMACOLOGY '97

## SAN DIEGO, CALIFORNIA

### MARCH 7 - 11, 1997

- 
- ❖ "Polymorphisms of drug metabolizing enzymes and their implications in man," (J. Goldstein). *Sponsored by ASPET Drug Metabolism Division*
  - ❖ "5HT<sub>2</sub> Receptor family," (E. Sanders-Bush, T. Blackburn).
  - ❖ "Antisense oligonucleotides at the clinical threshold," (E. Wickstrom).
  - ❖ "Polymorphisms/mutations in drug receptor - effector signaling," (S. Liggett, D. Abernethy).
  - ❖ "The genetic role of angiotensin in hypertension," (M. Printz).
  - ❖ "Molecular targets for HIV therapy," (C. Trapnell).
  - ❖ "Molecular and physiological mechanisms of first pass metabolism," (S. Wrighton, S. Hall).
  - ❖ "Adrenergic receptor desensitization," (B. Hoffman, R. Feldman).
  - ❖ "Pharmacological misinformation and drug policy," (A. Robison).  
*Sponsored by Committee on Public Affairs*
  - ❖ "Nitric Oxide: New discoveries and their clinical implications," (T. Michel).
  - ❖ "P<sub>2</sub>-purinergic receptors," (K. Harden).
  - ❖ "Biologically active peptides of the complement system," (J. Regal).
  - ❖ "Mech. of neurotoxicity of CNS stimulants," (J. Gibb).
  - ❖ "Expression of human enzymes involved in the transformation of drugs and other xenobiotics." (F. Guengerich). *Sponsored by Drug Metabolism Division*
  - ❖ "Cyclic ADP-ribose and calcium signaling," (H.C. Lee).
  - ❖ "Glutamate receptors and pain," (T. Yaksh).
  - ❖ "In vivo pharmacology of P-selectin antagonists," (R. Shebuski).
  - ❖ "Signal transduction systems activated by cell adhesion molecules," (R. Juliano).
  - ❖ "Interactions of neuronal systems at presynaptic receptors," (C.B. Smith, H. Saito).  
*Sponsored by Neuropharmacology Division*

Short Course: "Transcription Factors: Targets for Therapy," (L.J. Gudas).

ASPET Colloquium: Signaling and Macromolecular Structures in Pharmacology  
P. Taylor, A. Maccammon, R. Neubig, P. Sternweis  
*Sponsored by ASPET Section for Molecular Pharmacology*

**Conjoint Meeting with ASCPT  
Put on Your Calendar!  
Plan to Attend!**

**Guest Societies:**

British Pharmacological Society  
Japanese Pharmacological Society

**Abstract Deadline: November 20, 1996**

For more information, call the ASPET office at (301) 530-7060.